



Supplemental Material

Supplemental figures


Supplemental tables




Supplemental Figure 1. Antigen-specific CD4+ T-cell responses after re-stimulation with vaccine-matched peptide pools. Frequency of CD4+ T cells expressing at least 2 of the cytokines IL-2, TNF- α and IFN- γ in response to Rv2660c at study days 0, 14/28, 70 and 168 after vaccination (day 28 for BCG group and day 14 for all other groups). Respective response rates are indicated above each box plot. Each box plot is based upon data from responders only and is superimposed on the distributions. The mid-line of the box denotes the median and the ends of the box denote the 25th and 75th percentiles. The whiskers that extend from the top and bottom of the box extend to the most extreme data points that are no more than 1.5 times the interquartile range. Comparisons to baseline of response rates were made using McNemar's test and magnitudes among responders with the Wilcoxon Signed rank test.




Supplemental Figure 2. Antigen-specific CD8+ T-cell responses in the H4:IC31, H56:IC31, BCG revaccinated and placebo groups. Frequency of CD8+ T cells expressing at least 2 of the cytokines IL-2, TNF- α and IFN- γ in response to (a) Ag85B, (b) TB10.4, (c) ESAT-6 or (d) Rv2660c at study days 0, 14/28, 70 and 168 after vaccination (day 28 for BCG group and day 14 for all other groups). Respective response rates are indicated above each box plot. Each box plot is based upon data from responders only and are superimposed on the distributions. The mid-line of the box denotes the median and the ends of the box denote the 25th and 75th percentiles. The whiskers that extend from the top and bottom of the box extend to the most extreme data points that are no more than 1.5 times the interquartile range.




Supplemental Figure 3. Cytokine expression of stimulated CD4+ T cells. Boxplots show the median and interquartile (IQR) of the percentage of CD4+ T cells expressing the combination of cytokines indicated on the x-axis. The magnitude is background-subtracted. Panels show Ag85B-specific responses among H4:IC31 and H56:IC31 recipients. These data are only from the H4:IC31 (n=3) and H56:IC31 (n=5) group participants that received only the first of the two injections specified by the protocol.




Supplemental Figure 4. H4- and H56-specific IgG1 binding antibody. Levels of binding antibody were measured using a binding antibody multiplex assay. Boxplots show the median and IQR of the net response on a log scale. Panels show response rates and net response magnitude to the H4 recombinant fusion protein (a) and the H56 recombinant fusion protein (b).



Supplemental Figure 5. H4- and H56-specific IgG3 binding antibody. Levels of binding antibody were measured using a binding antibody multiplex assay. Boxplots show the median and IQR of the net response on a log scale. Panels show response rates and net response magnitude to the H4 recombinant fusion protein (a) and the H56 recombinant fusion protein (b).



Supplemental Figure 6. H4- and H56-specific IgG4 binding antibody. Levels of binding antibody were measured using a binding antibody multiplex assay. Boxplots show the median and IQR of the net response on a log scale. Panels show response rates and net response magnitude to the H4 recombinant fusion protein (a) and the H56 recombinant fusion protein (b).



Supplemental Figure 7. H4- and H56-specific IgG2 binding antibody. Levels of binding antibody were measured using a binding antibody multiplex assay. Boxplots show the median and IQR of the net response on a log scale. Panels show response rates and net response magnitude to the H4 recombinant fusion protein (a) and the H56 recombinant fusion protein (b).

Supplemental Table 1. Overall incidence of related adverse events (solicited and unsolicited) by severity and dose at onset.

Variable	Placebo (N=12)	BCG (N=24)	H4:IC31 (N=24)	H56:IC31 (N=24)
Participants with at least 1 AE				
After any vaccination				
N1 ^a	12	24	24	24
Mild, n (%) ^b	4 (33·3)	15 (62·5)	14 (58·3)	7 (29·2)
Moderate, n (%) ^b	2 (16·7)	8 (33·3)	3 (12·5)	8 (33·3)
Severe, n (%) ^b	0	0	0	0
After study day 0 vaccination				
N1 ^a	12	24	24	24
Mild, n (%) ^b	5 (41·7)	15 (62·5)	13 (54·2)	8 (33·3)
Moderate, n (%) ^b	1 (8·3)	8 (33·3)	2 (8·3)	7 (29·2)
Severe, n (%) ^b	0	0	0	0
After study day 56 vaccination				
N1 ^a	11	NA	21	19
Mild, n (%) ^b	2 (18·2)	NA	7 (33·3)	6 (31·6)
Moderate, n (%) ^b	1 (9·1)	NA	1 (4·8)	1 (5·3)
Severe, n (%) ^b	0	NA	0	0

NA=not applicable

a. N1=Total number of participants within each treatment group in the Safety Analysis Set who received the applicable study vaccination.

b. Percentages based on N1.

Supplemental ICS Tables. Descriptive tables of the ICS data and longitudinal comparisons.

See following file.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 1

ICS Response Rates Using MIMOSA

Lab	Tcell	Peptide Pool	Cytokine	Day	Group	Response Rate	95% CI				
CH	CD4+	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0	Placebo	4/11 = 36.4%	(15.2%, 64.6%)				
					H4:IC31	5/23 = 21.7%	(9.7%, 41.9%)				
					H56:IC31	7/22 = 31.8%	(16.4%, 52.7%)				
								14	BCG	6/24 = 25.0%	(12.0%, 44.9%)
							Placebo		2/10 = 20.0%	(5.7%, 51.0%)	
							H4:IC31		1/22 = 4.5%	(0.8%, 21.8%)	
								28	H56:IC31	6/22 = 27.3%	(13.2%, 48.2%)
							BCG		10/20 = 50.0%	(29.9%, 70.1%)	
							Placebo		2/11 = 18.2%	(5.1%, 47.7%)	
								70	H4:IC31	4/20 = 20.0%	(8.1%, 41.6%)
							H56:IC31		10/20 = 50.0%	(29.9%, 70.1%)	
							BCG		10/18 = 55.6%	(33.7%, 75.4%)	
				168	Placebo	4/10 = 40.0%	(16.8%, 68.7%)				
			H4:IC31		0/20 = 0.0%	(0.0%, 16.1%)					
			H56:IC31		7/20 = 35.0%	(18.1%, 56.7%)					
			BCG		6/18 = 33.3%	(16.3%, 56.3%)					

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

95% confidence intervals are constructed using Wilson's score method.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 1

ICS Response Rates Using MIMOSA

Lab	Tcell	Peptide Pool	Cytokine	Day	Group	Response Rate	95% CI
		Ag85B	2_of_3_IFNg_IL2_TNFa	0	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	0/24 = 0.0%	(0.0%, 13.8%)
					H56:IC31	1/22 = 4.5%	(0.8%, 21.8%)
					BCG	0/24 = 0.0%	(0.0%, 13.8%)
				14	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	3/21 = 14.3%	(5.0%, 34.6%)
					H56:IC31	6/23 = 26.1%	(12.5%, 46.5%)
				28	BCG	0/20 = 0.0%	(0.0%, 16.1%)
				70	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	12/20 = 60.0%	(38.7%, 78.1%)
					H56:IC31	13/20 = 65.0%	(43.3%, 81.9%)
					BCG	0/18 = 0.0%	(0.0%, 17.6%)
				168	Placebo	0/10 = 0.0%	(0.0%, 27.8%)
					H4:IC31	15/23 = 65.2%	(44.9%, 81.2%)
					H56:IC31	9/21 = 42.9%	(24.5%, 63.5%)
					BCG	2/23 = 8.7%	(2.4%, 26.8%)

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

95% confidence intervals are constructed using Wilson's score method.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 1

ICS Response Rates Using MIMOSA

Lab	Tcell	Peptide Pool	Cytokine	Day	Group	Response Rate	95% CI
		ESAT-6	2_of_3_IFNg_IL2_TNFa	0	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	0/24 = 0.0%	(0.0%, 13.8%)
					H56:IC31	1/22 = 4.5%	(0.8%, 21.8%)
					BCG	0/24 = 0.0%	(0.0%, 13.8%)
				14	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	0/22 = 0.0%	(0.0%, 14.9%)
					H56:IC31	1/22 = 4.5%	(0.8%, 21.8%)
				28	BCG	0/20 = 0.0%	(0.0%, 16.1%)
				70	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	0/20 = 0.0%	(0.0%, 16.1%)
					H56:IC31	3/20 = 15.0%	(5.2%, 36.0%)
					BCG	0/18 = 0.0%	(0.0%, 17.6%)
				168	Placebo	0/10 = 0.0%	(0.0%, 27.8%)
					H4:IC31	1/23 = 4.3%	(0.8%, 21.0%)
					H56:IC31	2/21 = 9.5%	(2.7%, 28.9%)
					BCG	0/23 = 0.0%	(0.0%, 14.3%)

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

95% confidence intervals are constructed using Wilson's score method.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 1

ICS Response Rates Using MIMOSA

<i>Lab</i>	<i>Tcell</i>	<i>Peptide Pool</i>	<i>Cytokine</i>	<i>Day</i>	<i>Group</i>	<i>Response Rate</i>	<i>95% CI</i>
	Rv2660c	2_of_3_IFNg_IL2_TNFa		0	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	0/24 = 0.0%	(0.0%, 13.8%)
					H56:IC31	0/22 = 0.0%	(0.0%, 14.9%)
					BCG	0/24 = 0.0%	(0.0%, 13.8%)
				14	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	0/22 = 0.0%	(0.0%, 14.9%)
					H56:IC31	0/23 = 0.0%	(0.0%, 14.3%)
				28	BCG	0/20 = 0.0%	(0.0%, 16.1%)
				70	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	0/20 = 0.0%	(0.0%, 16.1%)
					H56:IC31	0/20 = 0.0%	(0.0%, 16.1%)
					BCG	0/18 = 0.0%	(0.0%, 17.6%)
				168	Placebo	0/10 = 0.0%	(0.0%, 27.8%)
					H4:IC31	0/23 = 0.0%	(0.0%, 14.3%)
					H56:IC31	0/21 = 0.0%	(0.0%, 15.5%)
					BCG	0/23 = 0.0%	(0.0%, 14.3%)

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

95% confidence intervals are constructed using Wilson's score method.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 1

ICS Response Rates Using MIMOSA

<i>Lab</i>	<i>Tcell</i>	<i>Peptide Pool</i>	<i>Cytokine</i>	<i>Day</i>	<i>Group</i>	<i>Response Rate</i>	<i>95% CI</i>
	TB 10.4	2_of_3_IFNg_IL2_TNFa		0	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	0/22 = 0.0%	(0.0%, 14.9%)
					H56:IC31	5/20 = 25.0%	(11.2%, 46.9%)
					BCG	1/23 = 4.3%	(0.8%, 21.0%)
				14	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	2/22 = 9.1%	(2.5%, 27.8%)
					H56:IC31	2/23 = 8.7%	(2.4%, 26.8%)
				28	BCG	4/20 = 20.0%	(8.1%, 41.6%)
				70	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	7/19 = 36.8%	(19.1%, 59.0%)
					H56:IC31	3/18 = 16.7%	(5.8%, 39.2%)
					BCG	2/17 = 11.8%	(3.3%, 34.3%)
				168	Placebo	0/10 = 0.0%	(0.0%, 27.8%)
					H4:IC31	7/23 = 30.4%	(15.6%, 50.9%)
					H56:IC31	2/21 = 9.5%	(2.7%, 28.9%)
					BCG	4/23 = 17.4%	(7.0%, 37.1%)

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

95% confidence intervals are constructed using Wilson's score method.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 1

ICS Response Rates Using MIMOSA

<i>Lab</i>	<i>Tcell</i>	<i>Peptide Pool</i>	<i>Cytokine</i>	<i>Day</i>	<i>Group</i>	<i>Response Rate</i>	<i>95% CI</i>
	CMV	2_of_3_IFNg_IL2_TNFa		0	Placebo	9/11 = 81.8%	(52.3%, 94.9%)
					H4:IC31	13/22 = 59.1%	(38.7%, 76.7%)
					H56:IC31	9/17 = 52.9%	(31.0%, 73.8%)
					BCG	17/21 = 81.0%	(60.0%, 92.3%)
				14	Placebo	6/10 = 60.0%	(31.3%, 83.2%)
					H4:IC31	15/20 = 75.0%	(53.1%, 88.8%)
					H56:IC31	13/22 = 59.1%	(38.7%, 76.7%)
				28	BCG	15/18 = 83.3%	(60.8%, 94.2%)
				70	Placebo	7/10 = 70.0%	(39.7%, 89.2%)
					H4:IC31	9/17 = 52.9%	(31.0%, 73.8%)
					H56:IC31	10/13 = 76.9%	(49.7%, 91.8%)
					BCG	14/16 = 87.5%	(64.0%, 96.5%)
				168	Placebo	7/ 9 = 77.8%	(45.3%, 93.7%)
					H4:IC31	13/16 = 81.3%	(57.0%, 93.4%)
					H56:IC31	9/12 = 75.0%	(46.8%, 91.1%)
					BCG	12/13 = 92.3%	(66.7%, 98.6%)

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

95% confidence intervals are constructed using Wilson's score method.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 1

ICS Response Rates Using MIMOSA

<i>Lab</i>	<i>Tcell</i>	<i>Peptide Pool</i>	<i>Cytokine</i>	<i>Day</i>	<i>Group</i>	<i>Response Rate</i>	<i>95% CI</i>
CD8+	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa		0	Placebo	1/11 = 9.1%	(1.6%, 37.7%)
					H4:IC31	5/23 = 21.7%	(9.7%, 41.9%)
					H56:IC31	2/22 = 9.1%	(2.5%, 27.8%)
					BCG	5/24 = 20.8%	(9.2%, 40.5%)
				14	Placebo	0/10 = 0.0%	(0.0%, 27.8%)
					H4:IC31	5/22 = 22.7%	(10.1%, 43.4%)
					H56:IC31	2/22 = 9.1%	(2.5%, 27.8%)
				28	BCG	2/20 = 10.0%	(2.8%, 30.1%)
				70	Placebo	1/11 = 9.1%	(1.6%, 37.7%)
					H4:IC31	6/20 = 30.0%	(14.5%, 51.9%)
					H56:IC31	1/20 = 5.0%	(0.9%, 23.6%)
					BCG	4/18 = 22.2%	(9.0%, 45.2%)
168	Placebo	0/10 = 0.0%	(0.0%, 27.8%)				
	H4:IC31	5/20 = 25.0%	(11.2%, 46.9%)				
	H56:IC31	1/20 = 5.0%	(0.9%, 23.6%)				
	BCG	0/18 = 0.0%	(0.0%, 17.6%)				

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

95% confidence intervals are constructed using Wilson's score method.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 1

ICS Response Rates Using MIMOSA

Lab	Tcell	Peptide Pool	Cytokine	Day	Group	Response Rate	95% CI
		Ag85B	2_of_3_IFNg_IL2_TNFa	0	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	0/24 = 0.0%	(0.0%, 13.8%)
					H56:IC31	0/22 = 0.0%	(0.0%, 14.9%)
					BCG	0/24 = 0.0%	(0.0%, 13.8%)
				14	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	0/21 = 0.0%	(0.0%, 15.5%)
					H56:IC31	0/23 = 0.0%	(0.0%, 14.3%)
				28	BCG	0/20 = 0.0%	(0.0%, 16.1%)
				70	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	0/20 = 0.0%	(0.0%, 16.1%)
					H56:IC31	0/20 = 0.0%	(0.0%, 16.1%)
					BCG	0/18 = 0.0%	(0.0%, 17.6%)
				168	Placebo	0/10 = 0.0%	(0.0%, 27.8%)
					H4:IC31	0/23 = 0.0%	(0.0%, 14.3%)
					H56:IC31	0/21 = 0.0%	(0.0%, 15.5%)
					BCG	0/23 = 0.0%	(0.0%, 14.3%)

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

95% confidence intervals are constructed using Wilson's score method.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 1

ICS Response Rates Using MIMOSA

Lab	Tcell	Peptide Pool	Cytokine	Day	Group	Response Rate	95% CI
		ESAT-6	2_of_3_IFNg_IL2_TNFa	0	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	0/24 = 0.0%	(0.0%, 13.8%)
					H56:IC31	0/22 = 0.0%	(0.0%, 14.9%)
					BCG	0/24 = 0.0%	(0.0%, 13.8%)
				14	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	0/22 = 0.0%	(0.0%, 14.9%)
					H56:IC31	0/22 = 0.0%	(0.0%, 14.9%)
				28	BCG	0/20 = 0.0%	(0.0%, 16.1%)
				70	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	0/20 = 0.0%	(0.0%, 16.1%)
					H56:IC31	0/20 = 0.0%	(0.0%, 16.1%)
					BCG	0/18 = 0.0%	(0.0%, 17.6%)
				168	Placebo	0/10 = 0.0%	(0.0%, 27.8%)
					H4:IC31	0/23 = 0.0%	(0.0%, 14.3%)
					H56:IC31	0/21 = 0.0%	(0.0%, 15.5%)
					BCG	0/23 = 0.0%	(0.0%, 14.3%)

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

95% confidence intervals are constructed using Wilson's score method.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 1

ICS Response Rates Using MIMOSA

Lab	Tcell	Peptide Pool	Cytokine	Day	Group	Response Rate	95% CI
		Rv2660c_2_of_3_IFNg_IL2_TNFa		0	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	0/24 = 0.0%	(0.0%, 13.8%)
					H56:IC31	0/22 = 0.0%	(0.0%, 14.9%)
					BCG	0/24 = 0.0%	(0.0%, 13.8%)
				14	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	0/22 = 0.0%	(0.0%, 14.9%)
					H56:IC31	0/23 = 0.0%	(0.0%, 14.3%)
				28	BCG	0/20 = 0.0%	(0.0%, 16.1%)
				70	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	0/20 = 0.0%	(0.0%, 16.1%)
					H56:IC31	0/20 = 0.0%	(0.0%, 16.1%)
					BCG	0/18 = 0.0%	(0.0%, 17.6%)
				168	Placebo	0/10 = 0.0%	(0.0%, 27.8%)
					H4:IC31	0/23 = 0.0%	(0.0%, 14.3%)
					H56:IC31	0/21 = 0.0%	(0.0%, 15.5%)
					BCG	0/23 = 0.0%	(0.0%, 14.3%)

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

95% confidence intervals are constructed using Wilson's score method.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 1

ICS Response Rates Using MIMOSA

Lab	Tcell	Peptide Pool	Cytokine	Day	Group	Response Rate	95% CI
	TB 10.4	2_of_3_IFNg_IL2_TNFa		0	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	0/22 = 0.0%	(0.0%, 14.9%)
					H56:IC31	0/20 = 0.0%	(0.0%, 16.1%)
					BCG	0/23 = 0.0%	(0.0%, 14.3%)
				14	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	0/22 = 0.0%	(0.0%, 14.9%)
					H56:IC31	0/23 = 0.0%	(0.0%, 14.3%)
				28	BCG	0/20 = 0.0%	(0.0%, 16.1%)
				70	Placebo	0/11 = 0.0%	(0.0%, 25.9%)
					H4:IC31	0/19 = 0.0%	(0.0%, 16.8%)
					H56:IC31	0/18 = 0.0%	(0.0%, 17.6%)
					BCG	0/17 = 0.0%	(0.0%, 18.4%)
				168	Placebo	0/10 = 0.0%	(0.0%, 27.8%)
					H4:IC31	0/23 = 0.0%	(0.0%, 14.3%)
					H56:IC31	0/21 = 0.0%	(0.0%, 15.5%)
					BCG	0/23 = 0.0%	(0.0%, 14.3%)

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

95% confidence intervals are constructed using Wilson's score method.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 1

ICS Response Rates Using MIMOSA

Lab	Tcell	Peptide Pool	Cytokine	Day	Group	Response Rate	95% CI
		CMV	2_of_3_IFNg_IL2_TNFa	0	Placebo	9/11 = 81.8%	(52.3%, 94.9%)
					H4:IC31	19/22 = 86.4%	(66.7%, 95.3%)
					H56:IC31	17/17 =100.0%	(81.6%, 100.0%)
					BCG	19/21 = 90.5%	(71.1%, 97.3%)
				14	Placebo	10/10 =100.0%	(72.2%, 100.0%)
					H4:IC31	18/20 = 90.0%	(69.9%, 97.2%)
					H56:IC31	22/22 =100.0%	(85.1%, 100.0%)
				28	BCG	17/18 = 94.4%	(74.2%, 99.0%)
				70	Placebo	10/10 =100.0%	(72.2%, 100.0%)
					H4:IC31	15/17 = 88.2%	(65.7%, 96.7%)
					H56:IC31	12/13 = 92.3%	(66.7%, 98.6%)
					BCG	13/16 = 81.3%	(57.0%, 93.4%)
				168	Placebo	9/ 9 =100.0%	(70.1%, 100.0%)
					H4:IC31	15/16 = 93.8%	(71.7%, 98.9%)
					H56:IC31	12/12 =100.0%	(75.8%, 100.0%)
					BCG	12/13 = 92.3%	(66.7%, 98.6%)

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

95% confidence intervals are constructed using Wilson's score method.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 2

Response Rates by Fisher's Exact Test, MIMOSA, and MIMOSA2

Lab	Tcell	Peptide	Cytokine	Day	Group	Fisher	MIMOSA	MIMOSA2
CH	CD4+	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0	Placebo	4/11 = 36.36%	4/11 = 36.36%	
					H4:IC31	5/23 = 21.74%	5/23 = 21.74%	
					H56:IC31	6/22 = 27.27%	7/22 = 31.82%	
					BCG	4/24 = 16.67%	6/24 = 25.00%	
				14	Placebo	2/10 = 20.00%	2/10 = 20.00%	0/10 = 0.00%
					H4:IC31	1/22 = 4.55%	1/22 = 4.55%	0/22 = 0.00%
					H56:IC31	6/22 = 27.27%	6/22 = 27.27%	2/22 = 9.09%
				28	BCG	10/20 = 50.00%	10/20 = 50.00%	7/20 = 35.00%
				70	Placebo	2/11 = 18.18%	2/11 = 18.18%	0/11 = 0.00%
					H4:IC31	3/20 = 15.00%	4/20 = 20.00%	0/20 = 0.00%
					H56:IC31	9/20 = 45.00%	10/20 = 50.00%	0/20 = 0.00%
					BCG	10/18 = 55.56%	10/18 = 55.56%	8/18 = 44.44%
168	Placebo	3/10 = 30.00%	4/10 = 40.00%	0/10 = 0.00%				
	H4:IC31	0/20 = 0.00%	0/20 = 0.00%	0/20 = 0.00%				
	H56:IC31	6/20 = 30.00%	7/20 = 35.00%	2/20 = 10.00%				
	BCG	6/18 = 33.33%	6/18 = 33.33%	4/18 = 22.22%				
	Ag85B	2_of_3_IFNg_IL2_TNFa		0	Placebo	0/11 = 0.00%	0/11 = 0.00%	

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 2

Response Rates by Fisher's Exact Test, MIMOSA, and MIMOSA2

Lab	Tcell	Peptide	Cytokine	Day	Group	Fisher	MIMOSA	MIMOSA2
					H4:IC31	0/24 = 0.00%	0/24 = 0.00%	
					H56:IC31	1/22 = 4.55%	1/22 = 4.55%	
					BCG	0/24 = 0.00%	0/24 = 0.00%	
				14	Placebo	0/11 = 0.00%	0/11 = 0.00%	0/11 = 0.00%
					H4:IC31	3/21 = 14.29%	3/21 = 14.29%	2/21 = 9.52%
					H56:IC31	6/23 = 26.09%	6/23 = 26.09%	1/23 = 4.35%
				28	BCG	0/20 = 0.00%	0/20 = 0.00%	0/20 = 0.00%
				70	Placebo	0/11 = 0.00%	0/11 = 0.00%	0/11 = 0.00%
					H4:IC31	12/20 = 60.00%	12/20 = 60.00%	12/20 = 60.00%
					H56:IC31	13/20 = 65.00%	13/20 = 65.00%	10/20 = 50.00%
					BCG	0/18 = 0.00%	0/18 = 0.00%	0/18 = 0.00%
				168	Placebo	0/10 = 0.00%	0/10 = 0.00%	0/10 = 0.00%
					H4:IC31	16/23 = 69.57%	15/23 = 65.22%	13/23 = 56.52%
					H56:IC31	8/21 = 38.10%	9/21 = 42.86%	6/21 = 28.57%
					BCG	2/23 = 8.70%	2/23 = 8.70%	2/23 = 8.70%
	ESAT-6	2_of_3_IFNg_IL2_TNFa		0	Placebo	0/11 = 0.00%	0/11 = 0.00%	
					H4:IC31	0/24 = 0.00%	0/24 = 0.00%	

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 2

Response Rates by Fisher's Exact Test, MIMOSA, and MIMOSA2

Lab	Tcell	Peptide	Cytokine	Day	Group	Fisher	MIMOSA	MIMOSA2
					H56:IC31	1/22 = 4.55%	1/22 = 4.55%	
					BCG	0/24 = 0.00%	0/24 = 0.00%	
				14	Placebo	0/11 = 0.00%	0/11 = 0.00%	0/11 = 0.00%
					H4:IC31	0/22 = 0.00%	0/22 = 0.00%	0/22 = 0.00%
					H56:IC31	1/22 = 4.55%	1/22 = 4.55%	1/22 = 4.55%
				28	BCG	0/20 = 0.00%	0/20 = 0.00%	0/20 = 0.00%
				70	Placebo	0/11 = 0.00%	0/11 = 0.00%	0/11 = 0.00%
					H4:IC31	0/20 = 0.00%	0/20 = 0.00%	0/20 = 0.00%
					H56:IC31	3/20 = 15.00%	3/20 = 15.00%	3/20 = 15.00%
					BCG	0/18 = 0.00%	0/18 = 0.00%	0/18 = 0.00%
				168	Placebo	0/10 = 0.00%	0/10 = 0.00%	0/10 = 0.00%
					H4:IC31	1/23 = 4.35%	1/23 = 4.35%	1/23 = 4.35%
					H56:IC31	2/21 = 9.52%	2/21 = 9.52%	2/21 = 9.52%
					BCG	0/23 = 0.00%	0/23 = 0.00%	0/23 = 0.00%
	Rv2660c	2_of_3_IFNg_IL2_TNFa		0	Placebo	0/11 = 0.00%	0/11 = 0.00%	
					H4:IC31	0/24 = 0.00%	0/24 = 0.00%	
					H56:IC31	0/22 = 0.00%	0/22 = 0.00%	

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 2

Response Rates by Fisher's Exact Test, MIMOSA, and MIMOSA2

Lab	Tcell	Peptide	Cytokine	Day	Group	Fisher	MIMOSA	MIMOSA2
					BCG	0/24 = 0.00%	0/24 = 0.00%	
				14	Placebo	0/11 = 0.00%	0/11 = 0.00%	0/11 = 0.00%
					H4:IC31	0/22 = 0.00%	0/22 = 0.00%	0/22 = 0.00%
					H56:IC31	0/23 = 0.00%	0/23 = 0.00%	0/23 = 0.00%
				28	BCG	0/20 = 0.00%	0/20 = 0.00%	0/20 = 0.00%
				70	Placebo	0/11 = 0.00%	0/11 = 0.00%	0/11 = 0.00%
					H4:IC31	0/20 = 0.00%	0/20 = 0.00%	0/20 = 0.00%
					H56:IC31	0/20 = 0.00%	0/20 = 0.00%	0/20 = 0.00%
					BCG	0/18 = 0.00%	0/18 = 0.00%	0/18 = 0.00%
				168	Placebo	0/10 = 0.00%	0/10 = 0.00%	0/10 = 0.00%
					H4:IC31	0/23 = 0.00%	0/23 = 0.00%	1/23 = 4.35%
					H56:IC31	0/21 = 0.00%	0/21 = 0.00%	0/21 = 0.00%
					BCG	0/23 = 0.00%	0/23 = 0.00%	0/23 = 0.00%
	TB 10.4	2_of_3_IFNg_IL2_TNFa		0	Placebo	0/11 = 0.00%	0/11 = 0.00%	
					H4:IC31	0/22 = 0.00%	0/22 = 0.00%	
					H56:IC31	5/20 = 25.00%	5/20 = 25.00%	
					BCG	1/23 = 4.35%	1/23 = 4.35%	

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 2

Response Rates by Fisher's Exact Test, MIMOSA, and MIMOSA2

Lab	Tcell	Peptide	Cytokine	Day	Group	Fisher	MIMOSA	MIMOSA2
				14	Placebo	0/11 = 0.00%	0/11 = 0.00%	0/11 = 0.00%
					H4:IC31	2/22 = 9.09%	2/22 = 9.09%	1/22 = 4.55%
					H56:IC31	2/23 = 8.70%	2/23 = 8.70%	0/23 = 0.00%
				28	BCG	4/20 = 20.00%	4/20 = 20.00%	4/20 = 20.00%
				70	Placebo	0/11 = 0.00%	0/11 = 0.00%	0/11 = 0.00%
					H4:IC31	7/19 = 36.84%	7/19 = 36.84%	7/19 = 36.84%
					H56:IC31	3/18 = 16.67%	3/18 = 16.67%	0/18 = 0.00%
					BCG	2/17 = 11.76%	2/17 = 11.76%	1/17 = 5.88%
				168	Placebo	0/10 = 0.00%	0/10 = 0.00%	0/10 = 0.00%
					H4:IC31	7/23 = 30.43%	7/23 = 30.43%	6/23 = 26.09%
					H56:IC31	3/21 = 14.29%	2/21 = 9.52%	0/21 = 0.00%
					BCG	4/23 = 17.39%	4/23 = 17.39%	2/23 = 8.70%
	CMV	2_of_3_IFNg_IL2_TNFa		0	Placebo	8/11 = 72.73%	9/11 = 81.82%	
					H4:IC31	12/22 = 54.55%	13/22 = 59.09%	
					H56:IC31	9/17 = 52.94%	9/17 = 52.94%	
					BCG	16/21 = 76.19%	17/21 = 80.95%	

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 2

Response Rates by Fisher's Exact Test, MIMOSA, and MIMOSA2

Lab	Tcell	Peptide	Cytokine	Day	Group	Fisher	MIMOSA	MIMOSA2
				14	Placebo	5/10 = 50.00%	6/10 = 60.00%	0/10 = 0.00%
					H4:IC31	12/20 = 60.00%	15/20 = 75.00%	2/20 = 10.00%
					H56:IC31	13/22 = 59.09%	13/22 = 59.09%	2/22 = 9.09%
				28	BCG	11/18 = 61.11%	15/18 = 83.33%	4/18 = 22.22%
				70	Placebo	7/10 = 70.00%	7/10 = 70.00%	1/10 = 10.00%
					H4:IC31	7/17 = 41.18%	9/17 = 52.94%	1/17 = 5.88%
					H56:IC31	9/13 = 69.23%	10/13 = 76.92%	1/13 = 7.69%
					BCG	13/16 = 81.25%	14/16 = 87.50%	3/16 = 18.75%
				168	Placebo	6/9 = 66.67%	7/9 = 77.78%	1/9 = 11.11%
					H4:IC31	10/16 = 62.50%	13/16 = 81.25%	4/16 = 25.00%
					H56:IC31	8/12 = 66.67%	9/12 = 75.00%	0/12 = 0.00%
					BCG	12/13 = 92.31%	12/13 = 92.31%	3/13 = 23.08%
CD8+	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa		0	Placebo	1/11 = 9.09%	1/11 = 9.09%	
					H4:IC31	3/23 = 13.04%	5/23 = 21.74%	
					H56:IC31	1/22 = 4.55%	2/22 = 9.09%	
					BCG	5/24 = 20.83%	5/24 = 20.83%	
				14	Placebo	0/10 = 0.00%	0/10 = 0.00%	0/10 = 0.00%

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 2

Response Rates by Fisher's Exact Test, MIMOSA, and MIMOSA2

Lab	Tcell	Peptide	Cytokine	Day	Group	Fisher	MIMOSA	MIMOSA2
					H4:IC31	4/22 = 18.18%	5/22 = 22.73%	0/22 = 0.00%
					H56:IC31	2/22 = 9.09%	2/22 = 9.09%	0/22 = 0.00%
				28	BCG	2/20 = 10.00%	2/20 = 10.00%	1/20 = 5.00%
				70	Placebo	1/11 = 9.09%	1/11 = 9.09%	0/11 = 0.00%
					H4:IC31	3/20 = 15.00%	6/20 = 30.00%	0/20 = 0.00%
					H56:IC31	1/20 = 5.00%	1/20 = 5.00%	0/20 = 0.00%
					BCG	4/18 = 22.22%	4/18 = 22.22%	0/18 = 0.00%
				168	Placebo	0/10 = 0.00%	0/10 = 0.00%	0/10 = 0.00%
					H4:IC31	3/20 = 15.00%	5/20 = 25.00%	1/20 = 5.00%
					H56:IC31	1/20 = 5.00%	1/20 = 5.00%	0/20 = 0.00%
					BCG	0/18 = 0.00%	0/18 = 0.00%	0/18 = 0.00%
	Ag85B	2_of_3_IFNg_IL2_TNFa		0	Placebo	0/11 = 0.00%	0/11 = 0.00%	
					H4:IC31	0/24 = 0.00%	0/24 = 0.00%	
					H56:IC31	0/22 = 0.00%	0/22 = 0.00%	
					BCG	0/24 = 0.00%	0/24 = 0.00%	
				14	Placebo	0/11 = 0.00%	0/11 = 0.00%	0/11 = 0.00%
					H4:IC31	0/21 = 0.00%	0/21 = 0.00%	0/21 = 0.00%

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 2

Response Rates by Fisher's Exact Test, MIMOSA, and MIMOSA2

Lab	Tcell	Peptide	Cytokine	Day	Group	Fisher	MIMOSA	MIMOSA2
					H56:IC31	0/23 = 0.00%	0/23 = 0.00%	0/23 = 0.00%
				28	BCG	0/20 = 0.00%	0/20 = 0.00%	0/20 = 0.00%
				70	Placebo	0/11 = 0.00%	0/11 = 0.00%	0/11 = 0.00%
					H4:IC31	0/20 = 0.00%	0/20 = 0.00%	0/20 = 0.00%
					H56:IC31	0/20 = 0.00%	0/20 = 0.00%	0/20 = 0.00%
					BCG	0/18 = 0.00%	0/18 = 0.00%	0/18 = 0.00%
				168	Placebo	0/10 = 0.00%	0/10 = 0.00%	0/10 = 0.00%
					H4:IC31	0/23 = 0.00%	0/23 = 0.00%	0/23 = 0.00%
					H56:IC31	0/21 = 0.00%	0/21 = 0.00%	0/21 = 0.00%
					BCG	0/23 = 0.00%	0/23 = 0.00%	0/23 = 0.00%
	ESAT-6	2_of_3_IFNg_IL2_TNFa		0	Placebo	0/11 = 0.00%	0/11 = 0.00%	
					H4:IC31	0/24 = 0.00%	0/24 = 0.00%	
					H56:IC31	0/22 = 0.00%	0/22 = 0.00%	
					BCG	0/24 = 0.00%	0/24 = 0.00%	
				14	Placebo	0/11 = 0.00%	0/11 = 0.00%	0/11 = 0.00%
					H4:IC31	0/22 = 0.00%	0/22 = 0.00%	0/22 = 0.00%
					H56:IC31	0/22 = 0.00%	0/22 = 0.00%	0/22 = 0.00%

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 2

Response Rates by Fisher's Exact Test, MIMOSA, and MIMOSA2

Lab	Tcell	Peptide	Cytokine	Day	Group	Fisher	MIMOSA	MIMOSA2
				28	BCG	0/20 = 0.00%	0/20 = 0.00%	0/20 = 0.00%
				70	Placebo	0/11 = 0.00%	0/11 = 0.00%	0/11 = 0.00%
					H4:IC31	0/20 = 0.00%	0/20 = 0.00%	0/20 = 0.00%
					H56:IC31	0/20 = 0.00%	0/20 = 0.00%	0/20 = 0.00%
					BCG	0/18 = 0.00%	0/18 = 0.00%	0/18 = 0.00%
				168	Placebo	0/10 = 0.00%	0/10 = 0.00%	0/10 = 0.00%
					H4:IC31	0/23 = 0.00%	0/23 = 0.00%	0/23 = 0.00%
					H56:IC31	0/21 = 0.00%	0/21 = 0.00%	0/21 = 0.00%
					BCG	0/23 = 0.00%	0/23 = 0.00%	0/23 = 0.00%
	Rv2660c	2_of_3_IFNg_IL2_TNFa		0	Placebo	0/11 = 0.00%	0/11 = 0.00%	
					H4:IC31	0/24 = 0.00%	0/24 = 0.00%	
					H56:IC31	0/22 = 0.00%	0/22 = 0.00%	
					BCG	0/24 = 0.00%	0/24 = 0.00%	
				14	Placebo	0/11 = 0.00%	0/11 = 0.00%	0/11 = 0.00%
					H4:IC31	0/22 = 0.00%	0/22 = 0.00%	0/22 = 0.00%
					H56:IC31	0/23 = 0.00%	0/23 = 0.00%	0/23 = 0.00%

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 2

Response Rates by Fisher's Exact Test, MIMOSA, and MIMOSA2

Lab	Tcell	Peptide	Cytokine	Day	Group	Fisher	MIMOSA	MIMOSA2
				28	BCG	0/20 = 0.00%	0/20 = 0.00%	0/20 = 0.00%
				70	Placebo	0/11 = 0.00%	0/11 = 0.00%	0/11 = 0.00%
					H4:IC31	0/20 = 0.00%	0/20 = 0.00%	0/20 = 0.00%
					H56:IC31	0/20 = 0.00%	0/20 = 0.00%	0/20 = 0.00%
					BCG	0/18 = 0.00%	0/18 = 0.00%	0/18 = 0.00%
				168	Placebo	0/10 = 0.00%	0/10 = 0.00%	0/10 = 0.00%
					H4:IC31	0/23 = 0.00%	0/23 = 0.00%	0/23 = 0.00%
					H56:IC31	0/21 = 0.00%	0/21 = 0.00%	0/21 = 0.00%
					BCG	0/23 = 0.00%	0/23 = 0.00%	0/23 = 0.00%
	TB 10.4	2_of_3_IFNg_IL2_TNFa		0	Placebo	0/11 = 0.00%	0/11 = 0.00%	
					H4:IC31	0/22 = 0.00%	0/22 = 0.00%	
					H56:IC31	0/20 = 0.00%	0/20 = 0.00%	
					BCG	0/23 = 0.00%	0/23 = 0.00%	
				14	Placebo	0/11 = 0.00%	0/11 = 0.00%	0/11 = 0.00%
					H4:IC31	0/22 = 0.00%	0/22 = 0.00%	0/22 = 0.00%
					H56:IC31	0/23 = 0.00%	0/23 = 0.00%	0/23 = 0.00%
				28	BCG	0/20 = 0.00%	0/20 = 0.00%	0/20 = 0.00%

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 2

Response Rates by Fisher's Exact Test, MIMOSA, and MIMOSA2

Lab	Tcell	Peptide	Cytokine	Day	Group	Fisher	MIMOSA	MIMOSA2
				70	Placebo	0/11 = 0.00%	0/11 = 0.00%	0/11 = 0.00%
					H4:IC31	0/19 = 0.00%	0/19 = 0.00%	0/19 = 0.00%
					H56:IC31	0/18 = 0.00%	0/18 = 0.00%	0/18 = 0.00%
					BCG	0/17 = 0.00%	0/17 = 0.00%	0/17 = 0.00%
				168	Placebo	0/10 = 0.00%	0/10 = 0.00%	0/10 = 0.00%
					H4:IC31	0/23 = 0.00%	0/23 = 0.00%	0/23 = 0.00%
					H56:IC31	0/21 = 0.00%	0/21 = 0.00%	0/21 = 0.00%
					BCG	0/23 = 0.00%	0/23 = 0.00%	0/23 = 0.00%
	CMV	2_of_3_IFNg_IL2_TNFa		0	Placebo	9/11 = 81.82%	9/11 = 81.82%	
					H4:IC31	18/22 = 81.82%	19/22 = 86.36%	
					H56:IC31	15/17 = 88.24%	17/17 = 100.0%	
					BCG	18/21 = 85.71%	19/21 = 90.48%	
				14	Placebo	10/10 = 100.0%	10/10 = 100.0%	5/10 = 50.00%
					H4:IC31	16/20 = 80.00%	18/20 = 90.00%	5/20 = 25.00%
					H56:IC31	22/22 = 100.0%	22/22 = 100.0%	2/22 = 9.09%
				28	BCG	16/18 = 88.89%	17/18 = 94.44%	2/18 = 11.11%

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 2

Response Rates by Fisher's Exact Test, MIMOSA, and MIMOSA2

Lab	Tcell	Peptide	Cytokine	Day	Group	Fisher	MIMOSA	MIMOSA2
				70	Placebo	10/10 = 100.0%	10/10 = 100.0%	2/10 = 20.00%
					H4:IC31	13/17 = 76.47%	15/17 = 88.24%	2/17 = 11.76%
					H56:IC31	12/13 = 92.31%	12/13 = 92.31%	1/13 = 7.69%
					BCG	13/16 = 81.25%	13/16 = 81.25%	2/16 = 12.50%
				168	Placebo	9/ 9 = 100.0%	9/ 9 = 100.0%	5/ 9 = 55.56%
					H4:IC31	15/16 = 93.75%	15/16 = 93.75%	4/16 = 25.00%
					H56:IC31	12/12 = 100.0%	12/12 = 100.0%	1/12 = 8.33%
					BCG	10/13 = 76.92%	12/13 = 92.31%	2/13 = 15.38%

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 3

Descriptive Statistics by T-cell subset, visit, and treatment arm

Lab	Tcell	Peptide Pool	Cytokine	Day	Treatment	n	Min	Max	Mean	Median			
CH	CD4+	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0	Placebo	11	-0.008	0.214	0.041	0.029			
					H4:IC31	23	-0.060	0.111	0.014	0.011			
					H56:IC31	22	-0.071	0.399	0.055	0.010			
					BCG	24	-0.062	0.144	0.024	0.008			
				14	Placebo	10	-0.008	0.088	0.024	0.021			
					H4:IC31	22	-0.041	0.063	0.009	0.005			
					H56:IC31	22	-0.037	0.315	0.045	0.025			
				28	BCG	20	-0.056	0.482	0.085	0.043			
					70	Placebo	11	-0.020	0.074	0.018	0.014		
						H4:IC31	20	-0.047	0.077	0.016	0.017		
				H56:IC31		20	-0.007	0.367	0.070	0.045			
					BCG	18	-0.037	0.508	0.107	0.041			
				168	Placebo	10	-0.070	0.062	0.024	0.034			
					H4:IC31	20	-0.009	0.046	0.016	0.014			
					H56:IC31	20	-0.030	0.184	0.048	0.030			
					BCG	18	-0.039	0.652	0.099	0.043			
					Ag85B	2_of_3_IFNg_IL2_TNFa	0	Placebo	11	-0.028	0.010	-0.007	-0.006

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 3

Descriptive Statistics by T-cell subset, visit, and treatment arm

Lab	Tcell	Peptide Pool	Cytokine	Day	Treatment	n	Min	Max	Mean	Median
					H4:IC31	24	-0.036	0.033	-0.006	-0.006
					H56:IC31	22	-0.048	0.060	-0.004	-0.002
					BCG	24	-0.072	0.013	-0.011	-0.004
				14	Placebo	11	-0.053	0.017	-0.007	-0.005
					H4:IC31	21	-0.023	0.068	0.015	0.007
					H56:IC31	23	-0.035	0.164	0.030	0.015
				28	BCG	20	-0.043	0.036	-0.003	-0.004
				70	Placebo	11	-0.075	0.007	-0.010	-0.002
					H4:IC31	20	-0.011	0.430	0.124	0.064
					H56:IC31	20	0.001	0.511	0.118	0.077
					BCG	18	-0.072	0.026	-0.005	-0.001
				168	Placebo	10	-0.022	0.009	-0.004	-0.002
					H4:IC31	23	-0.008	0.355	0.083	0.071
					H56:IC31	21	0.008	0.321	0.064	0.034
					BCG	23	-0.047	0.124	0.003	-0.005
	ESAT-6	2_of_3_IFNg_IL2_TNFa		0	Placebo	11	-0.033	0.011	-0.009	-0.006
					H4:IC31	24	-0.128	0.001	-0.017	-0.010

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 3

Descriptive Statistics by T-cell subset, visit, and treatment arm

Lab	Tcell	Peptide Pool	Cytokine	Day	Treatment	n	Min	Max	Mean	Median
					H56:IC31	22	-0.077	0.034	-0.012	-0.008
					BCG	24	-0.100	0.007	-0.018	-0.008
				14	Placebo	11	-0.041	0.001	-0.010	-0.002
					H4:IC31	22	-0.045	0.004	-0.018	-0.018
					H56:IC31	22	-0.060	0.087	-0.001	0.001
				28	BCG	20	-0.063	0.008	-0.014	-0.006
				70	Placebo	11	-0.088	0.011	-0.013	-0.003
					H4:IC31	20	-0.067	0.029	-0.014	-0.012
					H56:IC31	20	-0.029	0.086	0.025	0.016
					BCG	18	-0.057	0.013	-0.012	-0.007
				168	Placebo	10	-0.050	0.006	-0.007	-0.002
					H4:IC31	23	-0.048	0.068	-0.008	-0.008
					H56:IC31	21	-0.030	0.079	0.006	0.001
					BCG	23	-0.060	0.006	-0.012	-0.009
	Rv2660c	2_of_3_IFNg_IL2_TNFa		0	Placebo	11	-0.039	0.007	-0.015	-0.016
					H4:IC31	24	-0.121	0.004	-0.015	-0.008
					H56:IC31	22	-0.065	0.029	-0.015	-0.012

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 3

Descriptive Statistics by T-cell subset, visit, and treatment arm

Lab	Tcell	Peptide Pool	Cytokine	Day	Treatment	n	Min	Max	Mean	Median
					BCG	24	-0.098	0.005	-0.021	-0.007
				14	Placebo	11	-0.052	0.006	-0.010	-0.007
					H4:IC31	22	-0.061	0.004	-0.019	-0.014
					H56:IC31	23	-0.126	0.020	-0.018	-0.008
				28	BCG	20	-0.069	0.014	-0.015	-0.007
				70	Placebo	11	-0.068	0.003	-0.012	-0.002
					H4:IC31	20	-0.046	0.008	-0.016	-0.013
					H56:IC31	20	-0.048	0.019	-0.003	0.001
					BCG	18	-0.059	0.008	-0.014	-0.010
				168	Placebo	10	-0.028	0.001	-0.007	-0.006
					H4:IC31	23	-0.041	0.009	-0.010	-0.007
					H56:IC31	21	-0.061	0.005	-0.011	-0.008
					BCG	23	-0.057	0.003	-0.017	-0.016
	TB 10.4		2_of_3_IFNg_IL2_TNFa	0	Placebo	11	-0.032	0.038	0.002	0.002
					H4:IC31	22	-0.153	0.006	-0.015	-0.007
					H56:IC31	20	-0.064	0.170	0.012	-0.002
					BCG	23	-0.096	0.129	-0.009	-0.005

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 3

Descriptive Statistics by T-cell subset, visit, and treatment arm

Lab	Tcell	Peptide Pool	Cytokine	Day	Treatment	n	Min	Max	Mean	Median
				14	Placebo	11	-0.052	0.016	-0.006	-0.005
					H4:IC31	22	-0.035	0.078	0.002	-0.002
					H56:IC31	23	-0.108	0.194	0.004	0.004
				28	BCG	20	-0.049	0.240	0.033	0.016
				70	Placebo	11	-0.045	0.043	-0.003	-0.004
					H4:IC31	19	-0.048	0.184	0.057	0.035
					H56:IC31	18	-0.022	0.068	0.013	0.003
					BCG	17	-0.046	0.183	0.023	0.015
				168	Placebo	10	-0.040	0.031	-0.001	-0.001
					H4:IC31	23	-0.047	0.240	0.040	0.023
					H56:IC31	21	-0.039	0.164	0.013	0.002
					BCG	23	-0.033	0.182	0.020	0.003
	CMV		2_of_3_IFNg_IL2_TNFa	0	Placebo	11	0.022	0.786	0.191	0.127
					H4:IC31	22	-0.080	0.506	0.075	0.049
					H56:IC31	17	0.007	0.357	0.096	0.051
					BCG	21	-0.006	3.595	0.369	0.126

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 3

Descriptive Statistics by T-cell subset, visit, and treatment arm

Lab	Tcell	Peptide Pool	Cytokine	Day	Treatment	n	Min	Max	Mean	Median
				14	Placebo	10	0.010	0.511	0.119	0.094
					H4:IC31	20	-0.018	0.719	0.142	0.080
					H56:IC31	22	-0.050	0.401	0.095	0.077
				28	BCG	18	0.008	5.139	0.444	0.073
				70	Placebo	10	0.023	0.463	0.174	0.106
					H4:IC31	17	-0.011	0.492	0.082	0.048
					H56:IC31	13	0.020	0.441	0.113	0.055
					BCG	16	-0.004	1.493	0.244	0.097
				168	Placebo	9	0.025	0.884	0.206	0.078
					H4:IC31	16	0.011	0.710	0.166	0.097
					H56:IC31	12	0.013	0.689	0.151	0.074
					BCG	13	0.038	0.552	0.201	0.149
CD8+	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa		0	Placebo	11	-0.007	0.033	0.010	0.009
					H4:IC31	23	-0.048	0.056	0.013	0.010
					H56:IC31	22	-0.019	0.138	0.012	0.007
					BCG	24	-0.024	0.134	0.016	0.002
				14	Placebo	10	-0.004	0.004	0.001	0.002

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 3

Descriptive Statistics by T-cell subset, visit, and treatment arm

Lab	Tcell	Peptide Pool	Cytokine	Day	Treatment	n	Min	Max	Mean	Median
					H4:IC31	22	-0.005	0.128	0.022	0.003
					H56:IC31	22	-0.006	0.108	0.011	0.004
				28	BCG	20	-0.014	0.063	0.014	0.012
				70	Placebo	11	-0.004	0.029	0.008	0.006
					H4:IC31	20	-0.009	0.084	0.018	0.009
					H56:IC31	20	-0.034	0.116	0.010	0.004
					BCG	18	-0.002	0.070	0.017	0.012
				168	Placebo	10	-0.007	0.008	0.000	0.000
					H4:IC31	20	-0.007	0.073	0.019	0.009
					H56:IC31	20	-0.008	0.058	0.008	0.005
					BCG	18	-0.014	0.042	0.007	0.002
	Ag85B	2_of_3_IFNg_IL2_TNFa		0	Placebo	11	-0.003	0.009	0.001	0.000
					H4:IC31	24	-0.035	0.007	-0.002	0.000
					H56:IC31	22	-0.012	0.019	-0.002	-0.003
					BCG	24	-0.012	0.008	-0.003	-0.003
				14	Placebo	11	-0.007	0.020	0.001	0.001
					H4:IC31	21	-0.010	0.007	-0.001	-0.000

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 3

Descriptive Statistics by T-cell subset, visit, and treatment arm

Lab	Tcell	Peptide Pool	Cytokine	Day	Treatment	n	Min	Max	Mean	Median
					H56:IC31	23	-0.023	0.009	-0.000	0.000
				28	BCG	20	-0.008	0.024	0.001	-0.000
				70	Placebo	11	-0.005	0.004	-0.000	0.000
					H4:IC31	20	-0.010	0.012	-0.001	-0.001
					H56:IC31	20	-0.016	0.007	-0.002	-0.001
					BCG	18	-0.007	0.003	-0.001	0.000
				168	Placebo	10	-0.006	0.003	-0.000	0.000
					H4:IC31	23	-0.042	0.006	-0.003	-0.000
					H56:IC31	21	-0.008	0.008	0.000	0.000
					BCG	23	-0.011	0.015	-0.001	-0.001
	ESAT-6	2_of_3_IFNg_IL2_TNFa		0	Placebo	11	-0.004	0.003	0.000	-0.000
					H4:IC31	24	-0.047	0.006	-0.003	-0.001
					H56:IC31	22	-0.019	0.005	-0.003	-0.001
					BCG	24	-0.021	0.001	-0.004	-0.003
				14	Placebo	11	-0.006	0.007	-0.001	-0.000
					H4:IC31	22	-0.007	0.003	-0.002	-0.002
					H56:IC31	22	-0.031	0.006	-0.002	-0.000

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 3

Descriptive Statistics by T-cell subset, visit, and treatment arm

Lab	Tcell	Peptide Pool	Cytokine	Day	Treatment	n	Min	Max	Mean	Median
				28	BCG	20	-0.012	0.011	-0.000	-0.000
				70	Placebo	11	-0.005	0.006	0.001	0.001
					H4:IC31	20	-0.005	0.006	-0.001	-0.002
					H56:IC31	20	-0.037	0.003	-0.004	-0.000
					BCG	18	-0.011	0.008	-0.001	-0.001
				168	Placebo	10	-0.003	0.003	0.000	0.000
					H4:IC31	23	-0.095	0.005	-0.006	-0.002
					H56:IC31	21	-0.008	0.011	0.001	0.000
					BCG	23	-0.017	0.008	-0.001	-0.000
	Rv2660c	2_of_3_IFNg_IL2_TNFa		0	Placebo	11	-0.008	0.004	-0.002	-0.000
					H4:IC31	24	-0.055	0.007	-0.004	-0.001
					H56:IC31	22	-0.015	0.005	-0.002	-0.001
					BCG	24	-0.017	0.003	-0.004	-0.003
				14	Placebo	11	-0.007	0.008	-0.001	0.000
					H4:IC31	22	-0.009	0.003	-0.003	-0.003
					H56:IC31	23	-0.031	0.008	-0.003	-0.000

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 3

Descriptive Statistics by T-cell subset, visit, and treatment arm

Lab	Tcell	Peptide Pool	Cytokine	Day	Treatment	n	Min	Max	Mean	Median
				28	BCG	20	-0.011	0.008	-0.000	-0.000
				70	Placebo	11	-0.005	0.007	-0.000	-0.001
					H4:IC31	20	-0.011	0.003	-0.002	-0.000
					H56:IC31	20	-0.013	0.003	-0.002	-0.001
					BCG	18	-0.011	0.006	-0.001	0.000
				168	Placebo	10	-0.004	0.005	0.000	0.000
					H4:IC31	23	-0.064	0.013	-0.003	-0.000
					H56:IC31	21	-0.008	0.012	-0.000	0.000
					BCG	23	-0.009	0.006	-0.001	-0.000
	TB 10.4	2_of_3_IFNg_IL2_TNFa		0	Placebo	11	-0.010	0.004	-0.001	0.000
					H4:IC31	22	-0.060	0.004	-0.005	-0.002
					H56:IC31	20	-0.019	0.007	-0.003	-0.002
					BCG	23	-0.016	0.017	-0.003	-0.002
				14	Placebo	11	-0.006	0.007	-0.002	-0.003
					H4:IC31	22	-0.010	0.005	-0.002	-0.001
					H56:IC31	23	-0.031	0.004	-0.003	-0.000
				28	BCG	20	-0.012	0.007	-0.001	-0.000

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 3

Descriptive Statistics by T-cell subset, visit, and treatment arm

Lab	Tcell	Peptide Pool	Cytokine	Day	Treatment	n	Min	Max	Mean	Median
				70	Placebo	11	-0.005	0.003	-0.002	-0.001
					H4:IC31	19	-0.012	0.008	-0.003	-0.003
					H56:IC31	18	-0.018	0.001	-0.003	-0.000
					BCG	17	-0.008	0.005	-0.001	-0.001
				168	Placebo	10	-0.006	0.004	-0.000	0.000
					H4:IC31	23	-0.072	0.008	-0.004	-0.001
					H56:IC31	21	-0.008	0.009	-0.000	0.000
					BCG	23	-0.014	0.010	-0.001	0.000
	CMV	2_of_3_IFNg_IL2_TNFa		0	Placebo	11	-0.000	3.996	1.567	1.364
					H4:IC31	22	-0.005	2.503	0.596	0.344
					H56:IC31	17	0.050	2.498	0.875	0.624
					BCG	21	-0.007	4.488	1.390	0.953
				14	Placebo	10	0.036	3.490	1.561	1.199
					H4:IC31	20	0.006	2.583	0.670	0.405
					H56:IC31	22	0.091	3.729	1.271	0.812
				28	BCG	18	0.013	3.394	1.001	0.806

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 3

Descriptive Statistics by T-cell subset, visit, and treatment arm

Lab	Tcell	Peptide Pool	Cytokine	Day	Treatment	n	Min	Max	Mean	Median
				70	Placebo	10	0.032	4.111	1.749	1.324
					H4:IC31	17	0.003	2.410	0.613	0.352
					H56:IC31	13	0.023	3.881	1.156	0.713
					BCG	16	0.003	3.372	1.241	0.831
				168	Placebo	9	0.681	3.149	1.944	1.740
					H4:IC31	16	0.013	3.823	0.959	0.490
					H56:IC31	12	0.070	5.171	1.462	0.730
					BCG	13	0.022	4.464	1.037	0.668

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

<i>Lab</i>	<i>Group</i>	<i>Pub ID</i>	<i>T cell</i>	<i>Day</i>	<i>Peptide Pool</i>	<i>Cytokine</i>	<i>% Cytokine Response</i>	<i>% Response Neg Ctrl</i>	<i>% Response Bkgd Adj</i>
CH	BCG	042002	CD4+	28	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.137	0.033	0.104
				168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.124	0.044	0.079
			CD8+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.136	0.002	0.134
				28	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.049	0.004	0.045
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.039	0.000	0.039
		042005	CD4+	28	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.063	0.028	0.035
			CD8+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.075	0.012	0.063
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.075	0.005	0.070
		042016	CD4+	70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.045	0.008	0.038
			CD8+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.042	0.001	0.040
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.038	0.001	0.037
		042022	CD4+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.110	0.048	0.062
				28	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.212	0.025	0.187
				168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.134	0.026	0.108
		042026	CD4+	28	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.125	0.014	0.111
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.050	0.006	0.044
		042027	CD4+	168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.690	0.038	0.652
		042030	CD4+	28	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.110	0.028	0.081
		042031	CD8+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.033	0.000	0.033
		042035	CD4+	70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.120	0.035	0.085
			CD8+	28	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.077	0.014	0.063

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

<i>Lab</i>	<i>Group</i>	<i>Pub ID</i>	<i>T cell</i>	<i>Day</i>	<i>Peptide Pool</i>	<i>Cytokine</i>	<i>% Cytokine Response</i>	<i>% Response Neg Ctrl</i>	<i>% Response Bkgd Adj</i>
		042038	CD4+	28	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.167	0.046	0.120
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.127	0.027	0.100
		042043	CD4+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.166	0.022	0.144
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.387	0.016	0.371
				168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.353	0.026	0.327
		042053	CD4+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.159	0.016	0.144
				28	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.531	0.048	0.482
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.526	0.018	0.508
				168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.301	0.056	0.246
		042058	CD4+	70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.076	0.018	0.057
		042063	CD4+	28	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.138	0.043	0.095
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.285	0.052	0.232
			CD8+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.050	0.006	0.043
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.044	0.005	0.039
		042065	CD4+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.044	0.009	0.035
				28	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.119	0.019	0.100
				168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.074	0.005	0.070
		042066	CD4+	28	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.292	0.026	0.266
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.246	0.060	0.186
		042077	CD4+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.199	0.062	0.137
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.323	0.124	0.199

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

<i>Lab</i>	<i>Group</i>	<i>Pub ID</i>	<i>T cell</i>	<i>Day</i>	<i>Peptide Pool</i>	<i>Cytokine</i>	<i>% Cytokine Response</i>	<i>% Response Neg Ctrl</i>	<i>% Response Bkgd Adj</i>
		042084	CD4+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.115	0.025	0.090
	H4:IC31	042004	CD8+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.032	0.002	0.030
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.044	0.010	0.033
				168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.034	0.003	0.031
		042008	CD4+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.065	0.018	0.047
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.061	0.015	0.046
			CD8+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.051	0.000	0.051
				14	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.131	0.003	0.128
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.044	0.004	0.039
				168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.078	0.008	0.070
		042012	CD8+	14	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.060	0.007	0.053
				168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.078	0.006	0.073
		042018	CD8+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.022	0.000	0.022
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.036	0.000	0.036
		042021	CD4+	70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.125	0.064	0.061
			CD8+	70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.040	0.004	0.036
		042025	CD8+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.048	0.001	0.047
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.085	0.001	0.084
		042032	CD8+	14	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.097	0.006	0.091
		042036	CD4+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.161	0.050	0.111
		042037	CD4+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.078	0.018	0.060

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

<i>Lab</i>	<i>Group</i>	<i>Pub ID</i>	<i>T cell</i>	<i>Day</i>	<i>Peptide Pool</i>	<i>Cytokine</i>	<i>% Cytokine Response</i>	<i>% Response Neg Ctrl</i>	<i>% Response Bkgd Adj</i>
		042052	CD4+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.036	0.008	0.029
			CD8+	14	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.122	0.005	0.117
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.059	0.003	0.057
		042055	CD4+	70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.083	0.027	0.056
		042074	CD4+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.095	0.029	0.066
				14	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.072	0.009	0.063
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.120	0.043	0.077
			CD8+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.059	0.003	0.056
				14	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.046	0.000	0.046
				168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.047	0.000	0.047
		042076	CD8+	168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.049	0.004	0.045
H56:IC31		042013	CD4+	70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.070	0.011	0.059
		042014	CD8+	14	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.062	0.003	0.058
		042024	CD4+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.071	0.014	0.057
				14	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.145	0.019	0.126
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.074	0.010	0.065
				168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.152	0.024	0.128
		042028	CD4+	14	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.077	0.017	0.060
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.122	0.041	0.082
				168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.068	0.012	0.056
			CD8+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.035	0.002	0.033

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

<i>Lab</i>	<i>Group</i>	<i>Pub ID</i>	<i>T cell</i>	<i>Day</i>	<i>Peptide Pool</i>	<i>Cytokine</i>	<i>% Cytokine Response</i>	<i>% Response Neg Ctrl</i>	<i>% Response Bkgd Adj</i>
		042039	CD4+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.091	0.001	0.090
		042042	CD4+	14	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.114	0.048	0.066
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.196	0.074	0.121
		042048	CD4+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.436	0.058	0.378
				14	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.334	0.019	0.315
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.293	0.055	0.237
				168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.208	0.030	0.178
		042061	CD4+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.194	0.015	0.179
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.189	0.036	0.153
		042068	CD8+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.142	0.004	0.138
				14	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.108	0.000	0.108
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.116	0.000	0.116
				168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.058	0.000	0.058
		042071	CD4+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.074	0.030	0.044
				14	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.206	0.025	0.180
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.071	0.015	0.056
				168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.183	0.016	0.167
		042073	CD4+	70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.180	0.090	0.090
		042079	CD4+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.122	0.024	0.098
		042080	CD4+	70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.054	0.013	0.041
				168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.083	0.022	0.061

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

<i>Lab</i>	<i>Group</i>	<i>Pub ID</i>	<i>T cell</i>	<i>Day</i>	<i>Peptide Pool</i>	<i>Cytokine</i>	<i>% Cytokine Response</i>	<i>% Response Neg Ctrl</i>	<i>% Response Bkgd Adj</i>
		042081	CD4+	168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.064	0.027	0.037
		042083	CD4+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.416	0.018	0.399
				14	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.115	0.025	0.090
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.382	0.015	0.367
				168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.211	0.026	0.184
Placebo		042019	CD4+	14	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.095	0.007	0.088
				168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.084	0.022	0.062
		042029	CD8+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.035	0.001	0.033
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.032	0.002	0.029
		042033	CD4+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.053	0.008	0.045
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.052	0.010	0.042
		042045	CD4+	168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.065	0.023	0.042
		042070	CD4+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.276	0.062	0.214
		042072	CD4+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.059	0.005	0.054
				14	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.059	0.009	0.049
				70	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.080	0.006	0.074
				168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.071	0.014	0.057
		042075	CD4+	0	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.113	0.037	0.076
				168	BCG-Pasteur	2_of_3_IFNg_IL2_TNFa	0.064	0.011	0.054
BCG		042005	CD4+	28	TB 10.4	2_of_3_IFNg_IL2_TNFa	0.082	0.028	0.054
		042016	CD4+	168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.149	0.056	0.093

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
		042022	CD4+	28	TB 10.4	2_of_3_IFNg_IL2_TNFa	0.198	0.025	0.174
				168	TB 10.4	2_of_3_IFNg_IL2_TNFa	0.101	0.026	0.076
		042027	CD4+	168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.163	0.038	0.124
					TB 10.4	2_of_3_IFNg_IL2_TNFa	0.133	0.038	0.095
		042053	CD4+	0	TB 10.4	2_of_3_IFNg_IL2_TNFa	0.145	0.016	0.129
				28	TB 10.4	2_of_3_IFNg_IL2_TNFa	0.289	0.048	0.240
				70	TB 10.4	2_of_3_IFNg_IL2_TNFa	0.201	0.018	0.183
				168	TB 10.4	2_of_3_IFNg_IL2_TNFa	0.238	0.056	0.182
		042058	CD4+	70	TB 10.4	2_of_3_IFNg_IL2_TNFa	0.072	0.018	0.053
		042065	CD4+	28	TB 10.4	2_of_3_IFNg_IL2_TNFa	0.105	0.019	0.086
				168	TB 10.4	2_of_3_IFNg_IL2_TNFa	0.058	0.005	0.054
H4:IC31		042006	CD4+	14	Ag85B	2_of_3_IFNg_IL2_TNFa	0.132	0.064	0.068
				168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.132	0.050	0.081
		042008	CD4+	70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.143	0.015	0.128
					TB 10.4	2_of_3_IFNg_IL2_TNFa	0.180	0.015	0.165
				168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.120	0.048	0.071
					TB 10.4	2_of_3_IFNg_IL2_TNFa	0.135	0.048	0.087
		042012	CD4+	70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.247	0.041	0.207
				168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.123	0.031	0.092
					TB 10.4	2_of_3_IFNg_IL2_TNFa	0.098	0.031	0.067
		042018	CD4+	70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.093	0.033	0.060

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
				168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.168	0.033	0.134
		042021	CD4+	70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.290	0.064	0.226
					TB 10.4	2_of_3_IFNg_IL2_TNFa	0.248	0.064	0.184
				168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.187	0.061	0.127
					TB 10.4	2_of_3_IFNg_IL2_TNFa	0.153	0.061	0.092
		042025	CD4+	70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.257	0.011	0.246
					TB 10.4	2_of_3_IFNg_IL2_TNFa	0.127	0.011	0.116
				168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.170	0.023	0.147
		042032	CD4+	70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.496	0.065	0.430
					TB 10.4	2_of_3_IFNg_IL2_TNFa	0.236	0.065	0.171
				168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.376	0.020	0.355
					TB 10.4	2_of_3_IFNg_IL2_TNFa	0.187	0.020	0.167
		042036	CD4+	168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.093	0.031	0.062
		042037	CD4+	168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.100	0.027	0.072
		042047	CD4+	14	Ag85B	2_of_3_IFNg_IL2_TNFa	0.096	0.035	0.061
					TB 10.4	2_of_3_IFNg_IL2_TNFa	0.110	0.035	0.075
				168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.091	0.018	0.073
					TB 10.4	2_of_3_IFNg_IL2_TNFa	0.070	0.018	0.052
		042049	CD4+	70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.094	0.016	0.077
					TB 10.4	2_of_3_IFNg_IL2_TNFa	0.068	0.016	0.051
		042050	CD4+	70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.067	0.016	0.051

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
		042055	CD4+	70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.301	0.027	0.274
					TB 10.4	2_of_3_IFNg_IL2_TNFa	0.147	0.027	0.120
				168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.156	0.015	0.140
					TB 10.4	2_of_3_IFNg_IL2_TNFa	0.105	0.015	0.090
		042059	CD4+	14	TB 10.4	2_of_3_IFNg_IL2_TNFa	0.152	0.074	0.078
				70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.098	0.029	0.069
					TB 10.4	2_of_3_IFNg_IL2_TNFa	0.197	0.029	0.168
				168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.075	0.025	0.051
					ESAT-6	2_of_3_IFNg_IL2_TNFa	0.092	0.025	0.068
					TB 10.4	2_of_3_IFNg_IL2_TNFa	0.265	0.025	0.240
		042074	CD4+	14	Ag85B	2_of_3_IFNg_IL2_TNFa	0.075	0.009	0.066
				70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.204	0.043	0.161
				168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.129	0.016	0.113
		042076	CD4+	70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.342	0.057	0.284
				168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.232	0.028	0.204
		042082	CD4+	168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.067	0.021	0.046
H56:IC31		042013	CD4+	70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.157	0.011	0.146
		042014	CD4+	14	Ag85B	2_of_3_IFNg_IL2_TNFa	0.037	0.011	0.027
				70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.086	0.017	0.069
					ESAT-6	2_of_3_IFNg_IL2_TNFa	0.083	0.017	0.066
				168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.047	0.007	0.040

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
		042015	CD4+	70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.104	0.030	0.074
		042023	CD4+	0	TB 10.4	2_of_3_IFNg_IL2_TNFa	0.070	0.015	0.055
				14	TB 10.4	2_of_3_IFNg_IL2_TNFa	0.072	0.016	0.056
				70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.135	0.011	0.124
					TB 10.4	2_of_3_IFNg_IL2_TNFa	0.073	0.011	0.062
				168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.094	0.025	0.069
		042024	CD4+	14	ESAT-6	2_of_3_IFNg_IL2_TNFa	0.106	0.019	0.087
				70	ESAT-6	2_of_3_IFNg_IL2_TNFa	0.060	0.010	0.051
		042028	CD4+	14	Ag85B	2_of_3_IFNg_IL2_TNFa	0.051	0.017	0.034
				70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.145	0.041	0.104
				168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.057	0.012	0.046
		042039	CD4+	0	Ag85B	2_of_3_IFNg_IL2_TNFa	0.062	0.001	0.060
					ESAT-6	2_of_3_IFNg_IL2_TNFa	0.035	0.001	0.034
					TB 10.4	2_of_3_IFNg_IL2_TNFa	0.046	0.001	0.045
				70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.254	0.048	0.207
				168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.226	0.085	0.141
		042042	CD4+	14	Ag85B	2_of_3_IFNg_IL2_TNFa	0.172	0.048	0.124
				70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.426	0.074	0.352
				168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.292	0.059	0.233
		042044	CD4+	70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.071	0.010	0.061
				168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.055	0.013	0.042

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
		042048	CD4+	0	TB 10.4	2_of_3_IFNg_IL2_TNFa	0.228	0.058	0.170
				14	Ag85B	2_of_3_IFNg_IL2_TNFa	0.102	0.019	0.083
					TB 10.4	2_of_3_IFNg_IL2_TNFa	0.213	0.019	0.194
				168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.123	0.030	0.093
					TB 10.4	2_of_3_IFNg_IL2_TNFa	0.194	0.030	0.164
		042061	CD4+	0	TB 10.4	2_of_3_IFNg_IL2_TNFa	0.069	0.015	0.054
				70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.253	0.036	0.217
					TB 10.4	2_of_3_IFNg_IL2_TNFa	0.098	0.036	0.062
		042068	CD4+	70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.098	0.004	0.094
		042071	CD4+	70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.136	0.015	0.121
				168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.078	0.016	0.063
		042073	CD4+	168	ESAT-6	2_of_3_IFNg_IL2_TNFa	0.140	0.061	0.079
					TB 10.4	2_of_3_IFNg_IL2_TNFa	0.138	0.061	0.077
		042079	CD4+	0	TB 10.4	2_of_3_IFNg_IL2_TNFa	0.103	0.024	0.078
				70	TB 10.4	2_of_3_IFNg_IL2_TNFa	0.086	0.017	0.068
		042080	CD4+	14	Ag85B	2_of_3_IFNg_IL2_TNFa	0.095	0.031	0.064
				70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.088	0.013	0.076
		042083	CD4+	14	Ag85B	2_of_3_IFNg_IL2_TNFa	0.189	0.025	0.164
				70	Ag85B	2_of_3_IFNg_IL2_TNFa	0.525	0.015	0.511
					ESAT-6	2_of_3_IFNg_IL2_TNFa	0.081	0.015	0.066
				168	Ag85B	2_of_3_IFNg_IL2_TNFa	0.348	0.026	0.321

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
					ESAT-6	2_of_3_IFNg_IL2_TNFa	0.089	0.026	0.062
BCG	042002	CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.585	0.002	0.583	
			28	CMV	2_of_3_IFNg_IL2_TNFa	0.389	0.004	0.385	
			70	CMV	2_of_3_IFNg_IL2_TNFa	0.658	0.000	0.658	
	042005	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.374	0.026	0.349	
			28	CMV	2_of_3_IFNg_IL2_TNFa	0.528	0.028	0.500	
			70	CMV	2_of_3_IFNg_IL2_TNFa	0.519	0.032	0.488	
			168	CMV	2_of_3_IFNg_IL2_TNFa	0.572	0.020	0.552	
		CD8+	28	CMV	2_of_3_IFNg_IL2_TNFa	0.025	0.000	0.025	
			168	CMV	2_of_3_IFNg_IL2_TNFa	0.037	0.002	0.035	
	042016	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.117	0.014	0.103	
			28	CMV	2_of_3_IFNg_IL2_TNFa	0.166	0.041	0.125	
			70	CMV	2_of_3_IFNg_IL2_TNFa	0.096	0.008	0.088	
		CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.689	0.001	0.688	
			28	CMV	2_of_3_IFNg_IL2_TNFa	0.778	0.006	0.772	
			70	CMV	2_of_3_IFNg_IL2_TNFa	0.872	0.001	0.871	
	042022	CD4+	28	CMV	2_of_3_IFNg_IL2_TNFa	0.096	0.025	0.072	
			168	CMV	2_of_3_IFNg_IL2_TNFa	0.097	0.026	0.072	
		CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.787	0.003	0.785	
			28	CMV	2_of_3_IFNg_IL2_TNFa	0.689	0.000	0.689	
			168	CMV	2_of_3_IFNg_IL2_TNFa	0.441	0.004	0.437	

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
		042026	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.084	0.021	0.063
				28	CMV	2_of_3_IFNg_IL2_TNFa	0.039	0.014	0.026
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.072	0.006	0.065
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	2.923	0.003	2.920
				28	CMV	2_of_3_IFNg_IL2_TNFa	1.237	0.005	1.233
				70	CMV	2_of_3_IFNg_IL2_TNFa	2.767	0.004	2.762
		042027	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.054	0.020	0.034
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.029	0.002	0.027
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.050	0.009	0.040
		042030	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.150	0.025	0.126
				28	CMV	2_of_3_IFNg_IL2_TNFa	0.091	0.028	0.063
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.082	0.041	0.041
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.142	0.062	0.079
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	2.465	0.027	2.437
				28	CMV	2_of_3_IFNg_IL2_TNFa	1.533	0.009	1.523
				70	CMV	2_of_3_IFNg_IL2_TNFa	1.070	0.010	1.059
				168	CMV	2_of_3_IFNg_IL2_TNFa	1.513	0.010	1.503
		042031	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.371	0.020	0.351
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.489	0.036	0.454
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.497	0.000	0.497
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.630	0.006	0.624

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
		042035	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.215	0.054	0.161
				28	CMV	2_of_3_IFNg_IL2_TNFa	0.148	0.090	0.058
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.135	0.035	0.100
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.169	0.049	0.120
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	4.488	0.000	4.488
				28	CMV	2_of_3_IFNg_IL2_TNFa	3.408	0.014	3.394
				70	CMV	2_of_3_IFNg_IL2_TNFa	3.314	0.006	3.307
				168	CMV	2_of_3_IFNg_IL2_TNFa	4.467	0.003	4.464
		042038	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	1.234	0.034	1.200
				70	CMV	2_of_3_IFNg_IL2_TNFa	1.520	0.027	1.493
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.956	0.002	0.953
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.838	0.000	0.838
		042043	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.391	0.022	0.369
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.371	0.016	0.355
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	3.992	0.005	3.987
				70	CMV	2_of_3_IFNg_IL2_TNFa	3.374	0.002	3.372
		042051	CD4+	28	CMV	2_of_3_IFNg_IL2_TNFa	0.780	0.028	0.752
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.551	0.018	0.534
			CD8+	28	CMV	2_of_3_IFNg_IL2_TNFa	0.618	0.002	0.616
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.668	0.000	0.668
		042053	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.071	0.016	0.055

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
				28	CMV	2_of_3_IFNg_IL2_TNFa	0.105	0.048	0.057
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.070	0.018	0.052
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.048	0.008	0.040
				28	CMV	2_of_3_IFNg_IL2_TNFa	0.076	0.014	0.062
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.054	0.001	0.053
		042056	CD4+	70	CMV	2_of_3_IFNg_IL2_TNFa	0.223	0.087	0.136
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.233	0.076	0.157
			CD8+	28	CMV	2_of_3_IFNg_IL2_TNFa	1.914	0.004	1.910
				70	CMV	2_of_3_IFNg_IL2_TNFa	2.746	0.003	2.743
				168	CMV	2_of_3_IFNg_IL2_TNFa	2.042	0.014	2.028
		042058	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.211	0.019	0.193
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.112	0.018	0.094
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.979	0.004	0.975
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.826	0.002	0.824
		042062	CD4+	28	CMV	2_of_3_IFNg_IL2_TNFa	0.099	0.048	0.051
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.108	0.029	0.079
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.352	0.007	0.345
				28	CMV	2_of_3_IFNg_IL2_TNFa	0.383	0.002	0.381
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.337	0.000	0.337
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.412	0.000	0.412
		042063	CD4+	70	CMV	2_of_3_IFNg_IL2_TNFa	0.123	0.052	0.071

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
			CD8+	28	CMV	2_of_3_IFNg_IL2_TNFa	1.704	0.003	1.701
				70	CMV	2_of_3_IFNg_IL2_TNFa	2.350	0.005	2.345
		042065	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.089	0.009	0.080
				28	CMV	2_of_3_IFNg_IL2_TNFa	0.094	0.019	0.075
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.074	0.005	0.069
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.990	0.004	0.986
				28	CMV	2_of_3_IFNg_IL2_TNFa	1.315	0.002	1.314
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.695	0.004	0.691
		042066	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.221	0.063	0.157
				28	CMV	2_of_3_IFNg_IL2_TNFa	0.266	0.026	0.240
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.263	0.060	0.204
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.276	0.039	0.238
		042067	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.509	0.014	0.495
				28	CMV	2_of_3_IFNg_IL2_TNFa	0.302	0.013	0.289
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.312	0.020	0.292
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	3.302	0.009	3.293
				28	CMV	2_of_3_IFNg_IL2_TNFa	1.760	0.000	1.760
				168	CMV	2_of_3_IFNg_IL2_TNFa	1.644	0.000	1.644
		042069	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.073	0.009	0.063
				28	CMV	2_of_3_IFNg_IL2_TNFa	0.101	0.007	0.093
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.155	0.007	0.149

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	1.046	0.006	1.039
				28	CMV	2_of_3_IFNg_IL2_TNFa	1.323	0.003	1.321
				168	CMV	2_of_3_IFNg_IL2_TNFa	1.491	0.002	1.489
		042077	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	3.658	0.062	3.595
				28	CMV	2_of_3_IFNg_IL2_TNFa	5.197	0.058	5.139
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.683	0.003	0.680
				28	CMV	2_of_3_IFNg_IL2_TNFa	0.842	0.002	0.840
		042078	CD4+	28	CMV	2_of_3_IFNg_IL2_TNFa	0.456	0.103	0.353
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.313	0.082	0.231
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.314	0.073	0.241
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	2.392	0.007	2.385
				28	CMV	2_of_3_IFNg_IL2_TNFa	0.084	0.009	0.076
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.054	0.006	0.047
		042084	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.270	0.025	0.245
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	2.121	0.044	2.078
	H4:IC31	042003	CD4+	168	CMV	2_of_3_IFNg_IL2_TNFa	0.062	0.026	0.037
			CD8+	168	CMV	2_of_3_IFNg_IL2_TNFa	2.568	0.004	2.564
		042004	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.103	0.021	0.081
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.115	0.019	0.096
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.197	0.056	0.141
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.207	0.011	0.197

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	2.504	0.002	2.503
				14	CMV	2_of_3_IFNg_IL2_TNFa	1.944	0.010	1.934
				70	CMV	2_of_3_IFNg_IL2_TNFa	2.420	0.010	2.410
				168	CMV	2_of_3_IFNg_IL2_TNFa	3.826	0.003	3.823
		042006	CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.540	0.015	0.525
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.412	0.008	0.404
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.634	0.011	0.624
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.594	0.010	0.584
		042007	CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	2.066	0.069	1.998
		042008	CD4+	70	CMV	2_of_3_IFNg_IL2_TNFa	0.064	0.015	0.049
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.044	0.000	0.044
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.113	0.003	0.110
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.104	0.004	0.099
		042011	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.130	0.020	0.110
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.093	0.045	0.048
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.061	0.004	0.058
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.047	0.008	0.039
		042012	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.109	0.031	0.078
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.109	0.027	0.082
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.185	0.031	0.155
		042018	CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.334	0.000	0.334

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.996	0.007	0.990
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.352	0.000	0.352
		042021	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.141	0.043	0.098
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.163	0.050	0.113
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.139	0.064	0.075
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.040	0.002	0.037
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.043	0.002	0.040
		042025	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.060	0.010	0.050
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.077	0.024	0.053
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.108	0.011	0.097
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.175	0.001	0.174
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.151	0.007	0.144
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.187	0.001	0.185
		042032	CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.785	0.003	0.782
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.983	0.006	0.977
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.664	0.009	0.655
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.828	0.003	0.825
		042036	CD4+	168	CMV	2_of_3_IFNg_IL2_TNFa	0.069	0.031	0.038
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.307	0.004	0.303
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.290	0.005	0.285
		042037	CD4+	14	CMV	2_of_3_IFNg_IL2_TNFa	0.453	0.041	0.412

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.825	0.000	0.825
				14	CMV	2_of_3_IFNg_IL2_TNFa	2.588	0.005	2.583
				70	CMV	2_of_3_IFNg_IL2_TNFa	1.000	0.013	0.987
		042041	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.069	0.024	0.045
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.112	0.057	0.055
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.137	0.033	0.104
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.311	0.003	0.308
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.459	0.011	0.448
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.722	0.005	0.717
		042047	CD4+	14	CMV	2_of_3_IFNg_IL2_TNFa	0.754	0.035	0.719
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.526	0.018	0.508
			CD8+	14	CMV	2_of_3_IFNg_IL2_TNFa	0.049	0.006	0.043
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.057	0.002	0.055
		042049	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.526	0.020	0.506
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.460	0.055	0.405
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.509	0.016	0.492
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.757	0.048	0.710
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	1.248	0.000	1.248
				14	CMV	2_of_3_IFNg_IL2_TNFa	1.046	0.000	1.046
				70	CMV	2_of_3_IFNg_IL2_TNFa	1.293	0.002	1.291
				168	CMV	2_of_3_IFNg_IL2_TNFa	1.670	0.000	1.670

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
		042050	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.085	0.023	0.062
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.115	0.012	0.103
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.074	0.016	0.059
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.069	0.009	0.060
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.354	0.000	0.354
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.377	0.000	0.377
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.320	0.000	0.320
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.219	0.000	0.219
		042052	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.149	0.008	0.141
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.338	0.026	0.312
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.147	0.014	0.133
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.438	0.007	0.431
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.837	0.005	0.832
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.397	0.000	0.397
		042055	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.244	0.039	0.205
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.302	0.087	0.215
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.293	0.027	0.266
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.425	0.015	0.410
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.786	0.005	0.781
				14	CMV	2_of_3_IFNg_IL2_TNFa	1.287	0.000	1.287
				70	CMV	2_of_3_IFNg_IL2_TNFa	1.517	0.000	1.517

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
				168	CMV	2_of_3_IFNg_IL2_TNFa	2.119	0.002	2.117
		042057	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.094	0.040	0.054
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.129	0.034	0.095
		042059	CD4+	168	CMV	2_of_3_IFNg_IL2_TNFa	0.058	0.025	0.033
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	1.744	0.006	1.738
				14	CMV	2_of_3_IFNg_IL2_TNFa	1.512	0.004	1.508
				70	CMV	2_of_3_IFNg_IL2_TNFa	1.342	0.007	1.335
				168	CMV	2_of_3_IFNg_IL2_TNFa	1.462	0.007	1.455
		042074	CD4+	14	CMV	2_of_3_IFNg_IL2_TNFa	0.033	0.009	0.024
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.399	0.003	0.396
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.407	0.000	0.407
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.370	0.002	0.368
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.373	0.000	0.373
		042076	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.057	0.016	0.041
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.078	0.022	0.056
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.113	0.057	0.056
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.117	0.028	0.089
			CD8+	14	CMV	2_of_3_IFNg_IL2_TNFa	0.059	0.008	0.050
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.075	0.010	0.065
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.063	0.004	0.060
		042082	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.099	0.027	0.072

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.101	0.022	0.079
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.132	0.021	0.111
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.250	0.007	0.242
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.207	0.002	0.205
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.166	0.012	0.153
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.197	0.007	0.190
H56:IC31		042001	CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	1.484	0.000	1.484
				14	CMV	2_of_3_IFNg_IL2_TNFa	1.425	0.004	1.421
		042010	CD4+	14	CMV	2_of_3_IFNg_IL2_TNFa	0.028	0.001	0.027
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.033	0.003	0.030
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.987	0.000	0.987
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.781	0.000	0.781
				70	CMV	2_of_3_IFNg_IL2_TNFa	1.035	0.008	1.028
		042013	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.240	0.016	0.224
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.406	0.005	0.401
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.452	0.011	0.441
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.295	0.008	0.286
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	2.506	0.007	2.498
				14	CMV	2_of_3_IFNg_IL2_TNFa	2.988	0.000	2.988
				70	CMV	2_of_3_IFNg_IL2_TNFa	3.073	0.006	3.068
				168	CMV	2_of_3_IFNg_IL2_TNFa	2.123	0.000	2.123

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
		042014	CD4+	14	CMV	2_of_3_IFNg_IL2_TNFa	0.202	0.011	0.191
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.306	0.007	0.299
			CD8+	14	CMV	2_of_3_IFNg_IL2_TNFa	3.412	0.003	3.409
				168	CMV	2_of_3_IFNg_IL2_TNFa	5.174	0.003	5.171
		042015	CD4+	14	CMV	2_of_3_IFNg_IL2_TNFa	0.126	0.045	0.081
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.085	0.030	0.055
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.134	0.041	0.093
			CD8+	14	CMV	2_of_3_IFNg_IL2_TNFa	0.508	0.003	0.505
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.713	0.000	0.713
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.638	0.005	0.633
		042020	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.190	0.019	0.171
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.500	0.010	0.491
		042023	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.154	0.015	0.140
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.114	0.016	0.098
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	1.919	0.002	1.917
				14	CMV	2_of_3_IFNg_IL2_TNFa	1.887	0.004	1.883
		042024	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.139	0.014	0.125
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.282	0.019	0.263
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.443	0.009	0.435
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.515	0.010	0.506
		042028	CD4+	14	CMV	2_of_3_IFNg_IL2_TNFa	0.089	0.017	0.072

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.058	0.012	0.046
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.538	0.002	0.536
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.480	0.004	0.476
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.425	0.002	0.423
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.489	0.000	0.489
		042034	CD4+	70	CMV	2_of_3_IFNg_IL2_TNFa	0.026	0.006	0.020
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.115	0.000	0.115
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.522	0.004	0.517
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.440	0.010	0.431
		042039	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.114	0.001	0.112
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.394	0.000	0.394
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.296	0.013	0.283
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.233	0.000	0.233
		042040	CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.118	0.011	0.107
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.105	0.014	0.091
		042042	CD4+	14	CMV	2_of_3_IFNg_IL2_TNFa	0.324	0.048	0.276
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.748	0.059	0.689
			CD8+	14	CMV	2_of_3_IFNg_IL2_TNFa	0.211	0.017	0.193
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.330	0.010	0.320
		042044	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.365	0.007	0.357
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.318	0.010	0.308

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.117	0.000	0.117
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.080	0.000	0.080
		042046	CD4+	14	CMV	2_of_3_IFNg_IL2_TNFa	0.102	0.019	0.083
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.064	0.014	0.050
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.088	0.025	0.063
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.966	0.010	0.956
				14	CMV	2_of_3_IFNg_IL2_TNFa	1.136	0.000	1.136
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.576	0.000	0.576
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.826	0.000	0.826
		042048	CD4+	14	CMV	2_of_3_IFNg_IL2_TNFa	0.184	0.019	0.165
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.134	0.055	0.078
			CD8+	14	CMV	2_of_3_IFNg_IL2_TNFa	3.732	0.003	3.729
				70	CMV	2_of_3_IFNg_IL2_TNFa	3.891	0.010	3.881
		042061	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.066	0.015	0.051
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.625	0.001	0.624
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.590	0.004	0.585
		042068	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.102	0.028	0.074
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.133	0.018	0.115
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.167	0.004	0.163
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.113	0.028	0.085
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	1.039	0.004	1.035

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.842	0.000	0.842
				70	CMV	2_of_3_IFNg_IL2_TNFa	1.440	0.000	1.440
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.587	0.000	0.587
		042071	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.213	0.030	0.183
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.214	0.025	0.189
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.152	0.015	0.137
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.184	0.016	0.168
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.050	0.000	0.050
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.097	0.003	0.094
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.070	0.000	0.070
		042073	CD8+	14	CMV	2_of_3_IFNg_IL2_TNFa	2.122	0.000	2.122
				168	CMV	2_of_3_IFNg_IL2_TNFa	2.660	0.007	2.653
		042079	CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	1.257	0.001	1.256
				14	CMV	2_of_3_IFNg_IL2_TNFa	1.184	0.003	1.181
				70	CMV	2_of_3_IFNg_IL2_TNFa	1.383	0.002	1.381
				168	CMV	2_of_3_IFNg_IL2_TNFa	2.080	0.004	2.076
		042080	CD4+	14	CMV	2_of_3_IFNg_IL2_TNFa	0.199	0.031	0.168
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.110	0.013	0.097
			CD8+	14	CMV	2_of_3_IFNg_IL2_TNFa	3.019	0.008	3.012
				70	CMV	2_of_3_IFNg_IL2_TNFa	1.749	0.002	1.747
		042081	CD4+	168	CMV	2_of_3_IFNg_IL2_TNFa	0.060	0.027	0.033

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
			CD8+	14	CMV	2_of_3_IFNg_IL2_TNFa	0.527	0.009	0.518
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.596	0.002	0.594
		042083	CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	1.876	0.006	1.869
				14	CMV	2_of_3_IFNg_IL2_TNFa	1.701	0.006	1.695
				168	CMV	2_of_3_IFNg_IL2_TNFa	2.001	0.004	1.997
	Placebo	042009	CD8+	14	CMV	2_of_3_IFNg_IL2_TNFa	0.908	0.004	0.905
				168	CMV	2_of_3_IFNg_IL2_TNFa	1.276	0.006	1.270
		042017	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.847	0.062	0.786
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.529	0.018	0.511
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.500	0.038	0.463
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.416	0.017	0.399
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	3.996	0.000	3.996
				14	CMV	2_of_3_IFNg_IL2_TNFa	3.348	0.000	3.348
				70	CMV	2_of_3_IFNg_IL2_TNFa	3.497	0.000	3.497
				168	CMV	2_of_3_IFNg_IL2_TNFa	2.894	0.000	2.894
		042019	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.152	0.025	0.127
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.119	0.007	0.111
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.146	0.035	0.110
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	1.369	0.004	1.364
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.818	0.000	0.818
				70	CMV	2_of_3_IFNg_IL2_TNFa	1.099	0.005	1.093

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
		042029	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.158	0.062	0.095
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.154	0.043	0.111
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.140	0.038	0.102
			CD8+	14	CMV	2_of_3_IFNg_IL2_TNFa	0.041	0.005	0.036
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.034	0.002	0.032
		042033	CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	2.311	0.007	2.304
				14	CMV	2_of_3_IFNg_IL2_TNFa	2.735	0.001	2.734
				70	CMV	2_of_3_IFNg_IL2_TNFa	2.654	0.003	2.651
				168	CMV	2_of_3_IFNg_IL2_TNFa	2.413	0.004	2.409
		042045	CD4+	168	CMV	2_of_3_IFNg_IL2_TNFa	0.086	0.023	0.063
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.798	0.010	0.788
				14	CMV	2_of_3_IFNg_IL2_TNFa	1.103	0.008	1.094
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.678	0.004	0.674
				168	CMV	2_of_3_IFNg_IL2_TNFa	1.740	0.000	1.740
		042054	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.113	0.031	0.082
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.191	0.114	0.077
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.121	0.043	0.078
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	1.772	0.003	1.768
				14	CMV	2_of_3_IFNg_IL2_TNFa	1.395	0.006	1.389
				70	CMV	2_of_3_IFNg_IL2_TNFa	1.437	0.006	1.431
				168	CMV	2_of_3_IFNg_IL2_TNFa	1.129	0.000	1.129

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

Lab	Group	Pub ID	T cell	Day	Peptide Pool	Cytokine	% Cytokine Response	% Response Neg Ctrl	% Response Bkgd Adj
		042060	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.196	0.014	0.182
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.158	0.012	0.146
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.354	0.010	0.344
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.247	0.012	0.236
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.378	0.000	0.378
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.491	0.000	0.491
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.665	0.005	0.661
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.681	0.000	0.681
		042064	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.527	0.028	0.499
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.503	0.066	0.436
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.968	0.083	0.884
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	2.014	0.000	2.014
				70	CMV	2_of_3_IFNg_IL2_TNFa	2.125	0.000	2.125
				168	CMV	2_of_3_IFNg_IL2_TNFa	3.156	0.007	3.149
		042070	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.190	0.062	0.128
		042072	CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.029	0.005	0.024
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.038	0.006	0.032
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.048	0.014	0.034
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	1.076	0.003	1.073
				14	CMV	2_of_3_IFNg_IL2_TNFa	1.311	0.006	1.305
				70	CMV	2_of_3_IFNg_IL2_TNFa	1.220	0.003	1.217

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 4

Listing of Positive ICS Responses Using MIMOSA

<i>Lab</i>	<i>Group</i>	<i>Pub ID</i>	<i>T cell</i>	<i>Day</i>	<i>Peptide Pool</i>	<i>Cytokine</i>	<i>% Cytokine Response</i>	<i>% Response Neg Ctrl</i>	<i>% Response Bkgd Adj</i>
				168	CMV	2_of_3_IFNg_IL2_TNFa	1.097	0.005	1.093
	042075		CD4+	0	CMV	2_of_3_IFNg_IL2_TNFa	0.165	0.037	0.128
				14	CMV	2_of_3_IFNg_IL2_TNFa	0.181	0.019	0.162
				70	CMV	2_of_3_IFNg_IL2_TNFa	0.208	0.027	0.181
				168	CMV	2_of_3_IFNg_IL2_TNFa	0.120	0.011	0.109
			CD8+	0	CMV	2_of_3_IFNg_IL2_TNFa	3.556	0.007	3.549
				14	CMV	2_of_3_IFNg_IL2_TNFa	3.490	0.000	3.490
				70	CMV	2_of_3_IFNg_IL2_TNFa	4.115	0.004	4.111
				168	CMV	2_of_3_IFNg_IL2_TNFa	3.133	0.002	3.132

Unreliable samples are excluded.

Records are excluded if the number of T-cell subsets is < 1,000

These criteria are applied separately to CD4+ and CD8+ subsets.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

**Table 5
Comparison of Response Rates at Day 0 vs. Day 14 (BCG Day 28)**

Cytokine	Tcell	Peptide	Treatment Group	Sample Sizes		McNemar's Test p-values	
				Day 0	Day 14/28	Unadjusted	Adjusted
2_of_3_IFNg_IL2_TNFa	CD4+	BCG-Pasteur	Placebo	11	10	1.0000	1.0000
			H4:IC31	23	22	0.1250	1.0000
			H56:IC31	22	22	0.6250	1.0000
			BCG	24	20	0.0703	0.7031
		Ag85B	Placebo	11	11	.	.
			H4:IC31	24	21	0.2500	1.0000
			H56:IC31	22	23	0.2188	1.0000
			BCG	24	20	.	.
		ESAT-6	Placebo	11	11	.	.
			H4:IC31	24	22	.	.
			H56:IC31	22	22	1.0000	1.0000
			BCG	24	20	.	.
	Rv2660c	Placebo	11	11	.	.	
		H4:IC31	24	22	.	.	
		H56:IC31	22	23	.	.	
		BCG	24	20	.	.	
	TB 10.4	Placebo	11	11	.	.	
		H4:IC31	22	22	1.0000	1.0000	
		H56:IC31	20	23	0.2500	1.0000	
		BCG	23	20	0.2500	1.0000	

Missing: Not applicable; responses all positive or all negative.

There is no data for BCG at day 14. BCG responses are compared between day 0 and 28.

Positive responses are calculated using MIMOSA.

P-values are adjusted using the Holm method within groups of cell subset and cytokine.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report
Data as of February 5, 2018

Table 5
Comparison of Response Rates at Day 0 vs. Day 14 (BCG Day 28)

Cytokine	Tcell	Peptide	Treatment Group	Sample Sizes		McNemar's Test p-values	
				Day 0	Day 14/28	Unadjusted	Adjusted
CD8+	BCG-Pasteur	Placebo		11	10	1.0000	1.0000
			H4:IC31	23	22	1.0000	.
			H56:IC31	22	22	1.0000	1.0000
			BCG	24	20	0.3750	1.0000
	Ag85B	Placebo		11	11	.	.
			H4:IC31	24	21	.	.
			H56:IC31	22	23	.	.
			BCG	24	20	.	.
	ESAT-6	Placebo		11	11	.	.
			H4:IC31	24	22	.	.
			H56:IC31	22	22	.	.
			BCG	24	20	.	.
	Rv2660c	Placebo		11	11	.	.
			H4:IC31	24	22	.	.
			H56:IC31	22	23	.	.
			BCG	24	20	.	.
TB 10.4	Placebo		11	11	.	.	
		H4:IC31	22	22	.	.	
		H56:IC31	20	23	.	.	
		BCG	23	20	.	.	

Missing: Not applicable; responses all positive or all negative.
There is no data for BCG at day 14. BCG responses are compared between day 0 and 28.
Positive responses are calculated using MIMOSA.
P-values are adjusted using the Holm method within groups of cell subset and cytokine.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

**Table 6
Comparison of Response Magnitudes at Day 0 vs. Day 14 (BCG Day 28)**

Cytokine	Tcell	Peptide	Treatment Group	Sample Sizes Day 0 or 14/28	Wilcoxon Sign Rank p-values	
					Unadjusted	Adjusted
2_of_3_IFNg_IL2_TNFa	CD4+	BCG-Pasteur	Placebo	12	1.0000	1.0000
			H4:IC31	24	0.2253	1.0000
			H56:IC31	24	0.8176	1.0000
			BCG	24	0.0010	0.0164
		Ag85B	Placebo	12	1.0000	1.0000
			H4:IC31	24	0.0002	0.0031
			H56:IC31	24	0.0008	0.0151
			BCG	24	0.1641	1.0000
		ESAT-6	Placebo	12	0.1875	1.0000
			H4:IC31	24	0.5000	1.0000
			H56:IC31	24	0.0522	0.8359
			BCG	24	0.6875	1.0000
	Rv2660c	Placebo	12	0.2500	1.0000	
		H4:IC31	24	1.0000	1.0000	
		H56:IC31	24	0.9375	1.0000	
		BCG	24	1.0000	1.0000	
	TB 10.4	Placebo	12	0.3125	1.0000	
		H4:IC31	24	0.1099	1.0000	
		H56:IC31	24	0.8926	1.0000	

Positive responses are calculated using MIMOSA.

There is no data for BCG at day 14. BCG responses are compared between day 0 and 28.

ICS response magnitudes are censored at 0.01%

P-values are adjusted using the Holm method within groups of cell subset and cytokine.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

Table 6

Comparison of Response Magnitudes at Day 0 vs. Day 14 (BCG Day 28)

Cytokine	Tcell	Peptide	Treatment Group	Sample Sizes Day 0 or 14/28	Wilcoxon Sign Rank p-values	
					Unadjusted	Adjusted
			BCG	24	0.0002	0.0046
	CD8+	BCG-Pasteur	Placebo	12	0.0781	1.0000
			H4:IC31	24	0.9843	1.0000
			H56:IC31	24	0.2413	1.0000
			BCG	24	0.9217	1.0000
	Ag85B		Placebo	12	0.0781	1.0000
			H4:IC31	24	0.9780	1.0000
			H56:IC31	24	0.7615	1.0000
			BCG	24	0.1602	1.0000
	ESAT-6		Placebo	12	0.6875	1.0000
			H4:IC31	24	0.0977	1.0000
			H56:IC31	24	0.3828	1.0000
			BCG	24	0.0234	0.4688
	Rv2660c		Placebo	12	0.8438	1.0000
			H4:IC31	24	0.2324	1.0000
			H56:IC31	24	0.7910	1.0000
			BCG	24	0.0645	1.0000
	TB 10.4		Placebo	12	0.6250	1.0000
			H4:IC31	24	0.9515	1.0000

Positive responses are calculated using MIMOSA.

There is no data for BCG at day 14. BCG responses are compared between day 0 and 28.

ICS response magnitudes are censored at 0.01%

P-values are adjusted using the Holm method within groups of cell subset and cytokine.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report
Data as of February 5, 2018

Table 6
Comparison of Response Magnitudes at Day 0 vs. Day 14 (BCG Day 28)

Cytokine	Tcell	Peptide	Treatment Group	Sample	Wilcoxon Sign Rank		
				Sizes	p-values		
				Day 0 or 14/28	Unadjusted	Adjusted	
				H56:IC31	24	0.4258	1.0000
				BCG	24	1.0000	1.0000

Positive responses are calculated using MIMOSA.
There is no data for BCG at day 14. BCG responses are compared between day 0 and 28.
ICS response magnitudes are censored at 0.01%
P-values are adjusted using the Holm method within groups of cell subset and cytokine.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

**Table 7
Comparison of Response Rates at Day 0 vs. Day 70**

Cytokine	Tcell	Peptide	Treatment Group	Sample Sizes		McNemar's Test p-values	
				Day 0	Day 70	Unadjusted	Adjusted
2_of_3_IFNg_IL2_TNFa	CD4+	BCG-Pasteur	Placebo	11	11	1.0000	1.0000
			H4:IC31	23	20	1.0000	1.0000
			H56:IC31	22	20	0.6875	1.0000
			BCG	24	18	0.0156	0.1250
		Ag85B	Placebo	11	11	.	.
			H4:IC31	24	20	0.0005	0.0049
			H56:IC31	22	20	0.0010	0.0088
			BCG	24	18	.	.
		ESAT-6	Placebo	11	11	.	.
			H4:IC31	24	20	.	.
			H56:IC31	22	20	0.6250	1.0000
			BCG	24	18	.	.
	Rv2660c	Placebo	11	11	.	.	
		H4:IC31	24	20	.	.	
		H56:IC31	22	20	.	.	
		BCG	24	18	.	.	
	TB 10.4	Placebo	11	11	.	.	
		H4:IC31	22	19	0.0156	0.1250	
		H56:IC31	20	18	0.5000	1.0000	
		BCG	23	17	1.0000	1.0000	

Missing: Not applicable; responses all positive or all negative.

Positive responses are calculated using MIMOSA.

P-values are adjusted using the Holm method within groups of cell subset and cytokine.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

**Table 7
Comparison of Response Rates at Day 0 vs. Day 70**

Cytokine	Tcell	Peptide	Treatment Group	Sample Sizes		McNemar's Test p-values	
				Day 0	Day 70	Unadjusted	Adjusted
	CD8+	BCG-Pasteur	Placebo	11	11	.	.
			H4:IC31	23	20	1.0000	1.0000
			H56:IC31	22	20	1.0000	1.0000
			BCG	24	18	1.0000	1.0000
	Ag85B		Placebo	11	11	.	.
			H4:IC31	24	20	.	.
			H56:IC31	22	20	.	.
			BCG	24	18	.	.
	ESAT-6		Placebo	11	11	.	.
			H4:IC31	24	20	.	.
			H56:IC31	22	20	.	.
			BCG	24	18	.	.
	Rv2660c		Placebo	11	11	.	.
			H4:IC31	24	20	.	.
			H56:IC31	22	20	.	.
			BCG	24	18	.	.
	TB 10.4		Placebo	11	11	.	.
			H4:IC31	22	19	.	.
			H56:IC31	20	18	.	.
			BCG	23	17	.	.

Missing: Not applicable; responses all positive or all negative.

Positive responses are calculated using MIMOSA.

P-values are adjusted using the Holm method within groups of cell subset and cytokine.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

**Table 8
Comparison of Response Magnitudes at Day 0 vs. Day 70**

Cytokine	Tcell	Peptide	Treatment Group	Sample Sizes Day 0 or 70	Wilcoxon Sign Rank p-values	
					Unadjusted	Adjusted
2_of_3_IFNg_IL2_TNFa	CD4+	BCG-Pasteur	Placebo	12	0.8203	1.0000
			H4:IC31	23	0.5509	1.0000
			H56:IC31	23	0.6777	1.0000
			BCG	24	<.0001	0.0008
		Ag85B	Placebo	12	1.0000	1.0000
			H4:IC31	24	<.0001	0.0001
			H56:IC31	23	<.0001	<.0001
			BCG	24	0.1055	1.0000
		ESAT-6	Placebo	12	1.0000	1.0000
			H4:IC31	24	0.0938	1.0000
			H56:IC31	23	0.0013	0.0197
			BCG	24	0.3125	1.0000
	Rv2660c	Placebo	12	1.0000	1.0000	
		H4:IC31	24	0.5000	1.0000	
		H56:IC31	23	0.1272	1.0000	
		BCG	24	0.6875	1.0000	
	TB 10.4	Placebo	12	1.0000	1.0000	
		H4:IC31	23	0.0002	0.0039	
		H56:IC31	21	0.6772	1.0000	
		BCG	23	0.0001	0.0021	

Positive responses are calculated using MIMOSA.

ICS response magnitudes are censored at 0.01%

P-values are adjusted using the Holm method within groups of cell subset and cytokine.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report
Data as of February 5, 2018

Table 8
Comparison of Response Magnitudes at Day 0 vs. Day 70

Cytokine	Tcell	Peptide	Treatment Group	Sample Sizes Day 0 or 70	Wilcoxon Sign Rank p-values	
					Unadjusted	Adjusted
	CD8+	BCG-Pasteur	Placebo	12	0.2500	1.0000
			H4:IC31	23	0.9843	1.0000
			H56:IC31	23	0.0987	1.0000
			BCG	24	0.6095	1.0000
	Ag85B		Placebo	12	0.9375	1.0000
			H4:IC31	24	0.9032	1.0000
			H56:IC31	23	0.5469	1.0000
			BCG	24	0.6250	1.0000
	ESAT-6		Placebo	12	0.2188	1.0000
			H4:IC31	24	0.9697	1.0000
			H56:IC31	23	0.9375	1.0000
			BCG	24	0.0273	0.5469
	Rv2660c		Placebo	12	0.2500	1.0000
			H4:IC31	24	0.2661	1.0000
			H56:IC31	23	0.8438	1.0000
			BCG	24	0.1934	1.0000
	TB 10.4		Placebo	12	0.8438	1.0000
			H4:IC31	23	0.3203	1.0000
			H56:IC31	21	0.4375	1.0000
			BCG	23	0.7344	1.0000

Positive responses are calculated using MIMOSA.
ICS response magnitudes are censored at 0.01%
P-values are adjusted using the Holm method within groups of cell subset and cytokine.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

**Table 9
Comparison of Response Rates at Day 0 vs. Day 168**

Cytokine	Tcell	Peptide	Treatment Group	Sample Sizes		McNemar's Test p-values	
				Day 0	Day 168	Unadjusted	Adjusted
2_of_3_IFNg_IL2_TNFa	CD4+	BCG-Pasteur	Placebo	11	10	1.0000	1.0000
			H4:IC31	23	20	0.1250	1.0000
			H56:IC31	22	20	1.0000	1.0000
			BCG	24	18	0.5000	1.0000
		Ag85B	Placebo	11	10	.	.
			H4:IC31	24	23	<.0001	0.0007
			H56:IC31	22	21	0.0156	0.1719
			BCG	24	23	0.5000	1.0000
		ESAT-6	Placebo	11	10	.	.
			H4:IC31	24	23	1.0000	1.0000
			H56:IC31	22	21	1.0000	1.0000
			BCG	24	23	.	.
	Rv2660c	Placebo	11	10	.	.	
		H4:IC31	24	23	.	.	
		H56:IC31	22	21	.	.	
		BCG	24	23	.	.	
	TB 10.4	Placebo	11	10	.	.	
		H4:IC31	22	23	0.0313	0.3125	
		H56:IC31	20	21	0.1250	1.0000	
		BCG	23	23	0.2500	1.0000	

Missing: Not applicable; responses all positive or all negative.

Positive responses are calculated using MIMOSA.

P-values are adjusted using the Holm method within groups of cell subset and cytokine.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report
Data as of February 5, 2018

Table 9
Comparison of Response Rates at Day 0 vs. Day 168

Cytokine	Tcell	Peptide	Treatment Group	Sample Sizes		McNemar's Test p-values	
				Day 0	Day 168	Unadjusted	Adjusted
	CD8+	BCG-Pasteur	Placebo	11	10	.	.
			H4:IC31	23	20	1.0000	1.0000
			H56:IC31	22	20	1.0000	1.0000
			BCG	24	18	0.1250	0.3750
	Ag85B		Placebo	11	10	.	.
			H4:IC31	24	23	.	.
			H56:IC31	22	21	.	.
			BCG	24	23	.	.
	ESAT-6		Placebo	11	10	.	.
			H4:IC31	24	23	.	.
			H56:IC31	22	21	.	.
			BCG	24	23	.	.
	Rv2660c		Placebo	11	10	.	.
			H4:IC31	24	23	.	.
			H56:IC31	22	21	.	.
			BCG	24	23	.	.
TB 10.4		Placebo	11	10	.	.	
		H4:IC31	22	23	.	.	
		H56:IC31	20	21	.	.	
		BCG	23	23	.	.	

Missing: Not applicable; responses all positive or all negative.
Positive responses are calculated using MIMOSA.
P-values are adjusted using the Holm method within groups of cell subset and cytokine.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report

Data as of February 5, 2018

**Table 10
Comparison of Response Magnitudes at Day 0 vs. Day 168**

Cytokine	Tcell	Peptide	Treatment Group	Sample Sizes Day 0 or 168	Wilcoxon Sign Rank p-values	
					Unadjusted	Adjusted
2_of_3_IFNg_IL2_TNFa	CD4+	BCG-Pasteur	Placebo	12	0.3828	1.0000
			H4:IC31	24	0.9323	1.0000
			H56:IC31	24	0.8904	1.0000
			BCG	24	<.0001	0.0008
		Ag85B	Placebo	12	1.0000	1.0000
			H4:IC31	24	<.0001	<.0001
			H56:IC31	24	<.0001	0.0001
			BCG	24	0.7334	1.0000
		ESAT-6	Placebo	12	0.9375	1.0000
			H4:IC31	24	0.1250	1.0000
			H56:IC31	24	0.1514	1.0000
			BCG	24	1.0000	1.0000
	Rv2660c	Placebo	12	0.2500	1.0000	
		H4:IC31	24	0.1641	1.0000	
		H56:IC31	24	1.0000	1.0000	
		BCG	24	0.3125	1.0000	
	TB 10.4	Placebo	12	0.6250	1.0000	
		H4:IC31	24	<.0001	0.0004	
		H56:IC31	24	0.1531	1.0000	
		BCG	24	0.0003	0.0046	

Positive responses are calculated using MIMOSA.

ICS response magnitudes are censored at 0.01%

P-values are adjusted using the Holm method within groups of cell subset and cytokine.

HVTN 602 / AERAS A-042: A randomized, placebo-controlled, partially blinded phase 1b clinical trial to evaluate the safety and immunogenicity of BCG revaccination, H4:IC31, and H56:IC31 in healthy, HIV-1-uninfected adolescent participants

Lab PT Report
Data as of February 5, 2018

Table 10
Comparison of Response Magnitudes at Day 0 vs. Day 168

Cytokine	Tcell	Peptide	Treatment Group	Sample Sizes Day 0 or 168	Wilcoxon Sign Rank p-values	
					Unadjusted	Adjusted
CD8+	BCG-Pasteur	Placebo	12	0.1094	1.0000	
			H4:IC31	24	0.9265	1.0000
			H56:IC31	24	0.2247	1.0000
			BCG	24	0.2979	1.0000
	Ag85B	Placebo	12	0.8438	1.0000	
			H4:IC31	24	0.0574	1.0000
			H56:IC31	24	0.5771	1.0000
			BCG	24	0.6953	1.0000
	ESAT-6	Placebo	12	0.6875	1.0000	
			H4:IC31	24	0.3652	1.0000
			H56:IC31	24	0.0391	0.7813
			BCG	24	0.0840	1.0000
	Rv2660c	Placebo	12	0.8125	1.0000	
			H4:IC31	24	1.0000	1.0000
			H56:IC31	24	0.5469	1.0000
			BCG	24	0.3652	1.0000
TB 10.4	Placebo	12	0.5625	1.0000		
		H4:IC31	24	0.4631	1.0000	
		H56:IC31	24	0.1484	1.0000	
		BCG	24	1.0000	1.0000	

Positive responses are calculated using MIMOSA.
ICS response magnitudes are censored at 0.01%
P-values are adjusted using the Holm method within groups of cell subset and cytokine.